var title_f29_18_29984="FAP gene testing algorithm";
var content_f29_18_29984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    FAP gene testing algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 622px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AFAP: attenuate adenomatous polyposis; FAP: familial adenomatous polyposis.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. American Gastroenterological Association Guidelines: Reproduced with permission from the American Gastroenterological Association. Giardiello FM, Brensinger JD, Petersen GM. Gastroenterology 2001; 121:195. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29984=[""].join("\n");
var outline_f29_18_29984=null;
var title_f29_18_29985="Patient information: Nasal polyps (The Basics)";
var content_f29_18_29985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83335\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/62/10210\">",
"         Sinuses of the face",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/29/467\">",
"          Chronic sinusitis with polyps",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/53/17234\">",
"         Patient information: Sinusitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/58/42915\">",
"         Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nasal polyps (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nasal-polyps-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H90701821\">",
"      <span class=\"h1\">",
"       What are nasal polyps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nasal polyps are growths inside the nose or the sinuses. The sinuses are hollow areas in the bones of the face (",
"      <a class=\"graphic graphic_figure graphicRef75045 \" href=\"UTD.htm?9/62/10210\">",
"       figure 1",
"      </a>",
"      ). Polyps usually occur on both sides of the nose.",
"     </p>",
"     <p>",
"      Many people who have nasal polyps also have &ldquo;chronic sinusitis,&rdquo; a condition that can cause a stuffy nose, pain in the face, and discharge (mucus) from the nose (",
"      <a class=\"graphic graphic_figure graphicRef64506 \" href=\"UTD.htm?0/29/467\">",
"       figure 2",
"      </a>",
"      ). Doctors do not know why some people get nasal polyps.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90701836\">",
"      <span class=\"h1\">",
"       What are the symptoms of nasal polyps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Small polyps often do not cause any symptoms. Large polyps or having more than one polyp can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stuffiness or a blocked feeling in the nose",
"       </li>",
"       <li>",
"        Feelings of pressure or fullness in the face",
"       </li>",
"       <li>",
"        Trouble smelling",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90701851\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will probably be able to tell if you have nasal polyps by doing an exam. He or she will probably look into your nose with a special tool that has a light on it. He or she might also suggest that you have a CT scan. A CT scan is an imaging test that takes a picture of the inside of your nose and sinuses.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90701866\">",
"      <span class=\"h1\">",
"       How are nasal polyps treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nasal polyps are usually treated with medicines called steroids that come in pills or as a nose spray. Steroids used for nasal polyps are not the same steroids that athletes take to build muscle. These steroids can help shrink the polyps and make it easier to breathe.",
"     </p>",
"     <p>",
"      If steroid medicines don&rsquo;t shrink your polyps, your doctor might suggest surgery. But in most people, polyps tend to come back after surgery. So even if you have surgery, you must also keep using steroids, usually in the form of nose sprays or nose drops.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90701881\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people feel better if they rinse their nose and sinuses with salt water a few times a day. Ask your doctor or nurse if this would help in your case. If so, he or she can tell you the best way to do this.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90701896\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/53/17234?source=see_link\">",
"       Patient information: Sinusitis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=see_link\">",
"       Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/18/29985?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83335 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29985=[""].join("\n");
var outline_f29_18_29985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90701821\">",
"      What are nasal polyps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90701836\">",
"      What are the symptoms of nasal polyps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90701851\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90701866\">",
"      How are nasal polyps treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90701881\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90701896\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/62/10210\">",
"      Sinuses of the face",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/29/467\">",
"       Chronic sinusitis with polyps",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=related_link\">",
"      Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/53/17234?source=related_link\">",
"      Patient information: Sinusitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_18_29986="Cerebral atrophy in pediatric HIV";
var content_f29_18_29986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cerebral atrophy in pediatric HIV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Head computed tomography (CT) scan in an HIV-infected 8-year-old boy with generalized brain atrophy. Cerebral atrophy is common among children with HIV encephalopathy but is also observed among children with normal neurologic and developmental examinations.",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Meg Ferris, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29986=[""].join("\n");
var outline_f29_18_29986=null;
var title_f29_18_29987="Fluocinolone (ophthalmic): Drug information";
var content_f29_18_29987=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/32/3587?source=see_link\">",
"    see \"Fluocinolone (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Retisert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8097453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8100694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Chronic uveitis:",
"     </b>",
"     Ocular implant: One silicone-encased tablet (0.59 mg) surgically implanted into the posterior segment of the eye is designed to initially release 0.6 mcg/day, decreasing over 30 days to a steady-state release rate of 0.3-0.4 mcg/day for 30 months. Recurrence of uveitis denotes depletion of tablet, requiring reimplantation.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8100693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/32/3587?source=see_link\">",
"      see \"Fluocinolone (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Chronic uveitis:",
"     </b>",
"     Ocular implant: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8100695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, intravitreal, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retisert&reg;: 0.59 mg (1s) [enclosed in silicone elastomer]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8100697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Handle only by suture tab to avoid damaging the tablet integrity and adversely affecting release characteristics. Maintain strict adherence to aseptic handling of product; do not resterilize.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8097411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Treatment of chronic, noninfectious uveitis affecting the posterior segment of the eye",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluocinolone may be confused with fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8097486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &gt;50%: Ocular: Cataract, intraocular pressure increased, eye pain; procedural complications (eg, cataract fragments, implant migration, wound complications)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     10% to 35%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (33%), dizziness (5% to 15%), pain (5% to 15%), fever (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal  (5% to 15%): Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal (5% to 15%): Arthralgia, back pain, limb pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Abnormal sensation, blurred vision, conjunctival hemorrhage, conjunctival hyperemia, dry eye, eye irritation/inflammation, eyelid edema, glaucoma, hypotony, maculopathy, pruritus, ptosis, tearing, visual acuity decrease, vitreous floaters, vitreous hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory (5% to 15%): Cough, influenza, nasopharyngitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     5% to 9%: Ocular: Blepharitis, choroidal detachment, conjunctival edema/chemosis, corneal edema, eye discharge, eye swelling, macular edema, photophobia, photopsia, retinal hemorrhage, visual disturbance, vitreous opacitites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Frequency not specified: Miscellaneous: Secondary infection (bacterial, viral, or fungal)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8097466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinolone, other corticosteroids, or any component of the formulation; ocular infections of viral, bacterial, or fungal origin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8097467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Prolonged use may result in glaucoma and injury to the optic nerve. Visual defects in acuity and field of vision may occur (lasting 1-4 weeks postoperatively). Use with caution in presence of glaucoma (steroids increase intraocular pressure). Perforation may occur with topical steroids in diseases which thin the cornea or sclera. Steroid use may delay healing after cataract surgery. Intraocular pressure should be monitored if this product is used &gt;10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of the ocular implant have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular implant: May require IOP-lowering treatments within 2 years postimplantation. Recommend unilateral implantation only to minimize risk of postoperative infections developing in both eyes. Due to the potential for separation of the silicone cup reservoir from the suture tab, implant integrity should be monitored during eye exams.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8097492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8097462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted with this product; however, adverse events have been observed with corticosteroids in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8097464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8097465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of fluocinolone are absorbed following ocular administration to produce detectable amounts in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Implant",
"     </b>",
"     (Retisert Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.59 mg (1): $21900.00",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8100684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Releases fluocinolone acetonide at an initial rate of 0.6 mcg/day, decreasing over 30 days to a steady-state release rate of 0.3-0.4 mcg/day for 30 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Systemic absorption is negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Aqueous and vitreous humor",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/18/29987/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9128 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29987=[""].join("\n");
var outline_f29_18_29987=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097453\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100694\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100693\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100695\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100720\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097451\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100697\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097411\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097406\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097486\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097466\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097467\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299347\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097492\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097462\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097464\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097465\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322153\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100684\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9128|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/32/3587?source=related_link\">",
"      Fluocinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=related_link\">",
"      Fluocinolone (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1220?source=related_link\">",
"      Fluocinolone (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/15/29938?source=related_link\">",
"      Fluocinolone (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=related_link\">",
"      Fluocinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=related_link\">",
"      Fluocinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=related_link\">",
"      Fluocinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_18_29988="Dextromethorphan: Patient drug information";
var content_f29_18_29988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dextromethorphan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     see \"Dextromethorphan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"     see \"Dextromethorphan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Creo-Terpin&reg; [OTC];",
"     </li>",
"     <li>",
"      Creomulsion&reg; Adult Formula [OTC];",
"     </li>",
"     <li>",
"      Creomulsion&reg; for Children [OTC];",
"     </li>",
"     <li>",
"      Delsym&reg; [OTC];",
"     </li>",
"     <li>",
"      Father John's&reg; [OTC];",
"     </li>",
"     <li>",
"      Hold&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Nycoff [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's Long-Acting Cough [OTC];",
"     </li>",
"     <li>",
"      Robafen Cough [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Children's Cough Long-Acting [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Lingering Cold Long-Acting Cough [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Lingering Cold Long-Acting CoughGels&reg; [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Diabetes [OTC];",
"     </li>",
"     <li>",
"      Silphen-DM [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Cough Long Acting [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; 44&reg; Cough Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Cough [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cough [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701925",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dextromethorphan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695517",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place oral strip on your tongue and let melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (drops, solution, suspension, syrup) if you cannot swallow pills. Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11624 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29988=[""].join("\n");
var outline_f29_18_29988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158845\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018933\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018935\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018934\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018939\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018940\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018942\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018937\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018938\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018943\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018944\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=related_link\">",
"      Dextromethorphan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=related_link\">",
"      Dextromethorphan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_18_29989="Positive remodeling IVUS";
var content_f29_18_29989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of positive remodeling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravascular ultrasound images of the proximal reference and lesion site are shown. The remodeling ratio (EEM area lesion/EEM area proximal reference) is 1.32.",
"    <div class=\"footnotes\">",
"     EEM: external elastic membrane.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Schoenhagen P, Ziada KM, Vince DC, et al. J Am Coll Cardiol 2001; 38:297. Copyright &copy; 2001 American College of Cardiology.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29989=[""].join("\n");
var outline_f29_18_29989=null;
var title_f29_18_29990="Drugs for parasitic infections helminths";
var content_f29_18_29990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs for parasitic infections: Helminths",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by parasites. The table below lists first-choice and alternative drugs for most parasitic infections.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dosage",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        <em>",
"         Ancylostoma caninum",
"        </em>",
"        (Eosinophilic enterocolitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Mebendazole",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Endoscopic removal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Ancylostoma duodenale",
"         </em>",
"         , see Hookworm",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Angiostrongyliasis",
"        <em>",
"         (Angiostrongylus cantonensis, Angiostrongylus costaricensis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Anisakiasis (",
"        <em>",
"         Anisakis",
"        </em>",
"        spp.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treatment of choice:",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Surgical or endoscopic removal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ascariasis (",
"        <em>",
"         Ascaris lumbricoides",
"        </em>",
"        , roundworm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Mebendazole",
"       </td>",
"       <td>",
"        100 mg bid PO x 3 d or 500 mg once",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d or 500 mg once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Ivermectin",
"        <sup>",
"         [1,6]",
"        </sup>",
"       </td>",
"       <td>",
"        150 to 200 mcg/kg PO once",
"       </td>",
"       <td>",
"        150 to 200 mcg/kg PO once",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Baylisascariasis",
"        <em>",
"         (Baylisascaris procyonis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Capillariasis",
"        <em>",
"         (Capillaria philippinensis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Mebendazole",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        200 mg PO bid x 20 d",
"       </td>",
"       <td>",
"        200 mg PO bid x 20 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO daily x 10 d",
"       </td>",
"       <td>",
"        400 mg PO daily x 10 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Clonorchis sinensis",
"         </em>",
"         , see Fluke infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cutaneous larva migrans (creeping eruption, dog and cat hookworm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Drug of choice:",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO daily x 3 d",
"       </td>",
"       <td>",
"        400 mg PO daily x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Ivermectin",
"        <sup>",
"         [1,6]",
"        </sup>",
"       </td>",
"       <td>",
"        200 mcg/kg PO daily x 1 to 2 d",
"       </td>",
"       <td>",
"        200 mcg/kg PO daily x 1 to 2 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Cysticercosis, see Tapeworm infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Diphyllobothrium latum",
"         </em>",
"         , see Tapeworm infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        <em>",
"         Dracunculus medinensis",
"        </em>",
"        (guinea worm) infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Echinococcus, see Tapeworm infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        <em>",
"         Enterobius vermicularis",
"        </em>",
"        (pinworm) infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO once; repeat in&nbsp;two weeks",
"       </td>",
"       <td>",
"        400 mg PO once; repeat in&nbsp;two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Mebendazole",
"       </td>",
"       <td>",
"        100 mg PO once; repeat in&nbsp;two weeks",
"       </td>",
"       <td>",
"        100 mg PO once; repeat in&nbsp;two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Pyrantel pamoate",
"        <sup>",
"         [11*]",
"        </sup>",
"       </td>",
"       <td>",
"        11 mg/kg base PO once (max 1 g); repeat in&nbsp;two weeks",
"       </td>",
"       <td>",
"        11 mg/kg base PO once (max 1 g); repeat in&nbsp;two weeks",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Fasciola hepatica",
"         </em>",
"         , see Fluke infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Filariasis",
"        <sup>",
"         [12,13]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Wuchereria bancrofti",
"        </em>",
"        ,",
"        <em>",
"         Brugia malayi",
"        </em>",
"        ,",
"        <em>",
"         Brugia timori",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         [14]",
"        </sup>",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        6 mg/kg/d PO in 3 doses x 12 d",
"        <sup>",
"         [15,16]",
"        </sup>",
"       </td>",
"       <td>",
"        6 mg/kg/d PO in 3 doses x 12 d",
"        <sup>",
"         [15,16]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Loa loa",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         [17]",
"        </sup>",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        9 mg/kg/d PO in 3 doses x 12 d",
"        <sup>",
"         [15,16]",
"        </sup>",
"       </td>",
"       <td>",
"        9 mg/kg/d PO in 3 doses x 12 d",
"        <sup>",
"         [15,16]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Mansonella ozzardi",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 18",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Mansonella perstans",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Drug of choice:",
"        <sup>",
"         [19]",
"        </sup>",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 10 d",
"       </td>",
"       <td>",
"        400 mg PO bid x 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Mebendazole",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg PO bid x 30 d",
"       </td>",
"       <td>",
"        100 mg PO bid x 30 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Mansonella streptocerca",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Drug of choice:",
"        <sup>",
"         [20]",
"        </sup>",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        6 mg/kg/d PO in 3 doses x 12 d",
"        <sup>",
"         [16]",
"        </sup>",
"       </td>",
"       <td>",
"        6 mg/kg/d PO in 3 doses x 12 d",
"        <sup>",
"         [16]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Ivermectin",
"        <sup>",
"         [1,6]",
"        </sup>",
"       </td>",
"       <td>",
"        150 mcg/kg PO once",
"       </td>",
"       <td>",
"        150 mcg/kg PO once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Tropical Pulmonary Eosinophilia (TPE)",
"        <sup>",
"         [21]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        6 mg/kg/d in 3 doses x 12 to 21 d",
"        <sup>",
"         [16]",
"        </sup>",
"       </td>",
"       <td>",
"        6 mg/kg/d in 3 doses x 12 to 21 d",
"        <sup>",
"         [16]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Onchocerca volvulus",
"        </em>",
"        (River blindness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Ivermectin",
"        <sup>",
"         [6,22]",
"        </sup>",
"       </td>",
"       <td>",
"        150 mcg/kg PO once, repeated every 6 to 12 months until asymptomatic",
"       </td>",
"       <td>",
"        150 mcg/kg PO once, repeated every 6 to 12 months until asymptomatic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fluke, hermaphroditic, infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Clonorchis sinensis",
"        </em>",
"        (Chinese liver fluke)",
"        <sup>",
"         [23]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [24]",
"        </sup>",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 2 d",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 2 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        10 mg/kg/d PO x 7 d",
"       </td>",
"       <td>",
"        10 mg/kg/d PO x 7 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Fasciola hepatica (sheep liver fluke)",
"        <sup>",
"         [23]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         [25]",
"        </sup>",
"       </td>",
"       <td>",
"        Triclabendazole",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        10 mg/kg PO once or twice",
"       </td>",
"       <td>",
"        10 mg/kg PO once or twice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Bithionol",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        30 to 50 mg/kg on alternate days x 10 to 15 doses",
"       </td>",
"       <td>",
"        30-50 mg/kg on alternate days x 10 to 15 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Nitazoxanide",
"        <sup>",
"         [1,5]",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg PO bid x 7d",
"       </td>",
"       <td>",
"        1 to 3 yrs: 100 mg PO bid x 7 d",
"        <br/>",
"        4 to 11 yrs: 200 mg PO bid x 7 d",
"        <br/>",
"        &gt;12 yrs: 500 mg PO bid x 7 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Fasciolopsis buski",
"        </em>",
"        ,",
"        <em>",
"         Heterophyes heterophyes",
"        </em>",
"        ,",
"        <em>",
"         Metagonimus yokogawai",
"        </em>",
"        (intestinal flukes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [1,24]",
"        </sup>",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Metorchis conjunctus",
"        </em>",
"        (North American liver fluke)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [1,24]",
"        </sup>",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Nanophyetus salmincola",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [1,24]",
"        </sup>",
"       </td>",
"       <td>",
"        60 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"       <td>",
"        60 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Opisthorchis viverrini",
"        </em>",
"        (Southeast Asian liver fluke)",
"        <sup>",
"         [23]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [24]",
"        </sup>",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 2 d",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 2 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Paragonimiasis",
"        </em>",
"        (",
"        <em>",
"         P. westermani",
"        </em>",
"        ,",
"        <em>",
"         P. miyazaki",
"        </em>",
"        ,",
"        <em>",
"         P. skrjabini",
"        </em>",
"        ,",
"        <em>",
"         P. hueitungensis",
"        </em>",
"        ,",
"        <em>",
"         P. heterotrema",
"        </em>",
"        ,",
"        <em>",
"         P. utcerobilaterus",
"        </em>",
"        ,",
"        <em>",
"         P. Africanus",
"        </em>",
"        ,",
"        <em>",
"         P. Mexicanus",
"        </em>",
"        ,",
"        <em>",
"         P. Kellicotti",
"        </em>",
"        ) (lung fluke)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [1,24]",
"        </sup>",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 2 d",
"       </td>",
"       <td>",
"        75 mg/kg/d PO in 3 doses x 2 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Triclabendazole",
"        <sup>",
"         [26*]",
"        </sup>",
"       </td>",
"       <td>",
"        10 mg/kg PO once or twice",
"       </td>",
"       <td>",
"        10 mg/kg PO once or twice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Bithionol",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        30 to 50 mg/kg on alternate days x 10 to 15 doses",
"       </td>",
"       <td>",
"        30 to 50 mg/kg on alternate days x 10 to 15 doses",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gnathostomiasis",
"        <em>",
"         (Gnathostoma spinigerum)",
"        </em>",
"        <sup>",
"         [27]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Treatment of choice:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 21 d",
"       </td>",
"       <td>",
"        400 mg PO bid x 21 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Ivermectin",
"        <sup>",
"         [1,6]",
"        </sup>",
"       </td>",
"       <td>",
"        200 mcg/kg/d PO x 2 d",
"       </td>",
"       <td>",
"        200 mcg/kg/d PO x 2 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Either",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         &plusmn;",
"        </strong>",
"        Surgical removal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gongylonemiasis (",
"        <em>",
"         Gongylonema",
"        </em>",
"        sp.)",
"        <sup>",
"         [28]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Treatment of choice:",
"       </td>",
"       <td>",
"        Surgical removal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/d PO x 3 d",
"       </td>",
"       <td>",
"        400 mg/d PO x 3 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hookworm infection (",
"        <em>",
"         Ancylostoma duodenale",
"        </em>",
"        ,",
"        <em>",
"         Necator americanus",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Mebendazole",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d or 500 mg once",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d or 500 mg once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Pyrantel pamoate",
"        <sup>",
"         [1,11*]",
"        </sup>",
"       </td>",
"       <td>",
"        11 mg/kg (max 1 g) PO daily x 3 d",
"       </td>",
"       <td>",
"        11 mg/kg (max 1 g) PO daily x 3 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Hydatid cyst, see Tapeworm infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Hymenolepis nana",
"         </em>",
"         , see Tapeworm infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Loa loa",
"         </em>",
"         , see Filariasis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Necator americanus",
"         </em>",
"         , see Hookworm infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Onchocerca volvulus",
"         </em>",
"         , see Filariasis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Opisthorchis viverrini",
"         </em>",
"         , see Fluke infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Paragonimus westermani",
"         </em>",
"         , see Fluke infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Pinworm, see Enterobius",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         River Blindness, see Filariasis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Roundworm, see Ascariasis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Schistosomiasis",
"        <em>",
"         (Bilharziasis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         S. haematobium",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [24,29]",
"        </sup>",
"       </td>",
"       <td>",
"        40 mg/kg/d PO in 1 or 2 doses x 1 d",
"       </td>",
"       <td>",
"        40 mg/kg/d PO in 2 doses x 1 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         S. intercalatum",
"        </em>",
"        <sup>",
"         [30]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [24,29]",
"        </sup>",
"       </td>",
"       <td>",
"        40 mg/kg/d PO in 1 or 2 doses x 1 d",
"       </td>",
"       <td>",
"        40 mg/kg/d PO x 1 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         S. japonicum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [24,29]",
"        </sup>",
"       </td>",
"       <td>",
"        60 mg/kg/d PO in 2 or 3 doses x 1 d",
"       </td>",
"       <td>",
"        60 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         S. mansoni",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [24,29]",
"        </sup>",
"       </td>",
"       <td>",
"        40 mg/kg/d PO in 1 or 2 doses x 1 d",
"       </td>",
"       <td>",
"        40 mg/kg/d PO in 2 doses x 1 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Oxamniquine",
"        <sup>",
"         [31*]",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg PO once",
"        <sup>",
"         [32]",
"        </sup>",
"       </td>",
"       <td>",
"        20 mg/kg/d PO in 2 doses x 1 d",
"        <sup>",
"         [32]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         S. mekongi",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [24,29]",
"        </sup>",
"       </td>",
"       <td>",
"        60 mg/kg/d PO in 2 or 3 doses x 1 d",
"       </td>",
"       <td>",
"        60 mg/kg/d PO in 3 doses x 1 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Strongyloidiasis",
"        <em>",
"         (Strongyloides stercoralis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         [33]",
"        </sup>",
"       </td>",
"       <td>",
"        Ivermectin",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        200 mcg/kg/d PO x 2 d",
"       </td>",
"       <td>",
"        200 mcg/kg/d PO x 2 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 7 d",
"       </td>",
"       <td>",
"        400 mg PO bid x 7 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tapeworm infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <strong>",
"         Adult (intestinal stage)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        <strong>",
"         &mdash;",
"         <em>",
"          Diphyllobothrium latum",
"         </em>",
"         (fish),",
"         <em>",
"          Taenia saginata",
"         </em>",
"         (beef),",
"         <em>",
"          Taenia solium",
"         </em>",
"         (pork),",
"         <em>",
"          Dipylidium caninum",
"         </em>",
"         (dog)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [1,24]",
"        </sup>",
"       </td>",
"       <td>",
"        5 to 10 mg/kg PO once",
"       </td>",
"       <td>",
"        5 to 10 mg/kg PO once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Niclosamide",
"        <sup>",
"         [34*]",
"        </sup>",
"       </td>",
"       <td>",
"        2 g PO once",
"       </td>",
"       <td>",
"        50 mg/kg PO once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        <strong>",
"         &mdash;",
"         <em>",
"          Hymenolepis nana",
"         </em>",
"         (dwarf tapeworm)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Praziquantel",
"        <sup>",
"         [1,24]",
"        </sup>",
"       </td>",
"       <td>",
"        25 mg/kg PO once",
"       </td>",
"       <td>",
"        25 mg/kg PO once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Alternative:",
"        <sup>",
"         [35]",
"        </sup>",
"       </td>",
"       <td>",
"        Niclosamide",
"        <sup>",
"         [34*]",
"        </sup>",
"       </td>",
"       <td>",
"        2 g PO daily x 7 d",
"       </td>",
"       <td>",
"        11 to 34 kg: 1 g PO on day 1, then 500 mg/d PO x 6 days",
"        <br/>",
"        &gt;34 kg: 1.5 g PO on day 1 then 1 g/d PO x 6 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <strong>",
"         Larval (tissue stage)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        <strong>",
"         &mdash;",
"         <em>",
"          Echinococcus granulosus",
"         </em>",
"         (hydatid cyst)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Drug of choice:",
"        <sup>",
"         [36]",
"        </sup>",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 1 to 6 months",
"       </td>",
"       <td>",
"        15 mg/kg/d (max 800 mg) PO in 2 doses x 1 to 6 mos",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        <strong>",
"         &mdash;",
"         <em>",
"          Echinococcus multilocularis",
"         </em>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Treatment of choice:",
"       </td>",
"       <td>",
"        See footnote 37",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        <strong>",
"         &mdash;",
"         <em>",
"          Taenia solium (Cysticercosis)",
"         </em>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Treatment of choice:",
"       </td>",
"       <td>",
"        See footnote 38",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 8 to 30 d; can be repeated as necessary",
"       </td>",
"       <td>",
"        15 mg/kg/d (max 800 mg) PO in 2 doses x 8 to 30 d; can be repeated as necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Praziquantel",
"        <sup>",
"         [1,24]",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg/kg/d PO in 3 doses x 1 day then 50 mg/kg/d in 3 doses x 29 days",
"       </td>",
"       <td>",
"        100 mg/kg/d PO in 3 doses x 1 day then 50 mg/kg/d in 3 doses x 29 days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Toxocariasis, see Visceral larva migrans",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Trichinellosis",
"        <em>",
"         (Trichinella spiralis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"        <sup>",
"         [39]",
"        </sup>",
"       </td>",
"       <td>",
"        Steroids for severe symptoms, eg prednisone 30 to 60 mg PO daily x 10 to 15 d",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Plus",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 8 to 14 d",
"       </td>",
"       <td>",
"        400 mg PO bid x 8 to 14 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Mebendazole",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        200 to 400 mg PO tid x 3 d, then 400 to 500 mg tid x 10 d",
"       </td>",
"       <td>",
"        200 to 400 mg PO tid x 3 d, then 400 to 500 mg tid x 10 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Trichostrongylus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Pyrantel pamoate",
"        <sup>",
"         [1,11*]",
"        </sup>",
"       </td>",
"       <td>",
"        11 mg/kg base PO once (max 1 g)",
"       </td>",
"       <td>",
"        11 mg/kg PO once (max 1 g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Mebendazole",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"       <td>",
"        400 mg PO once",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Trichuriasis (",
"        <em>",
"         Trichuris trichiura",
"        </em>",
"        , whipworm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO x 3 d",
"       </td>",
"       <td>",
"        400 mg PO x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Mebendazole",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d",
"       </td>",
"       <td>",
"        100 mg PO bid x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Ivermectin",
"        <sup>",
"         [1,6]",
"        </sup>",
"       </td>",
"       <td>",
"        200 mcg/kg/d PO x 3 d",
"       </td>",
"       <td>",
"        200 mcg/kg/d PO x 3 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Visceral larva migrans",
"        <sup>",
"         [40]",
"        </sup>",
"        <em>",
"         (Toxocariasis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 5 d",
"       </td>",
"       <td>",
"        400 mg PO bid x 5 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Mebendazole",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        100 to 200 mg PO bid x 5 d",
"       </td>",
"       <td>",
"        100 to 200 mg PO bid x 5 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Whipworm, see Trichuriasis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Wuchereria bancrofti",
"         </em>",
"         , see Filariasis",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent; d: days; PO: by mouth; bid: twice daily; tid: three times daily.",
"     <br>",
"      * Availability problems.",
"      <br>",
"       <ol>",
"        <li>",
"         Not FDA-approved for this indication.",
"        </li>",
"        <li>",
"         Albendazole must be taken with food; a fatty meal increases oral bioavailability.",
"        </li>",
"        <li>",
"         <em>",
"          A. cantonensis",
"         </em>",
"         causes predominantly neurotropic disease (Wang QP,&nbsp;et al. Lancet Infect Dis 2008; 8:621).",
"         <em>",
"          A. costaricensis",
"         </em>",
"         causes gastrointestinal disease. Most patients infected with either species have a self-limited course and recover completely. Analgesics, corticosteroids and periodic removal of CSF can relieve symptoms from increased intracranial pressure (Ramirez-Avila L,&nbsp;et al. Clin Infect Dis 2009; 48:322). Treatment of",
"         <em>",
"          A. cantonensis",
"         </em>",
"         is controversial and varies across endemic areas. No antihelminthic drug is proven to be effective, and some patients have worsened with therapy. Mebendazole or albendazole each with or without a corticosteroid appear to shorten the course of infection (K Sawanyawisuth K, Sawanyawisuth K. Trans R Soc Trop Med Hyg 2008; 102:990; Chotmongkol V,&nbsp;et al. Am J Trop Med Hyg 2009; 81:443).",
"        </li>",
"        <li>",
"         Gastric anisakiasis can usually be diagnosed and treated by endoscopic removal of the worm. Enteric anisakiasis is more difficult to diagnose; it can be managed without worm removal as the worms eventually die. Surgery may be needed in the event of intestinal obstruction or peritonitis (Repiso Ortega A,&nbsp;et al. Gastroenterol Hepatol 2003; 26:341; Nakaji K. Intern Med 2009; 48:573). Successful treatment of anisakiasis with albendazole 400 mg PO bid x 3 to 5 d has been reported, but diagnosis was presumptive (Moore DA, et al. Lancet 2002; 360:54; Pacios E,&nbsp;et al. Clin Infect Dis 2005; 41:1825).",
"        </li>",
"        <li>",
"         Nitazoxanide may be effective against a variety of protozoan and helminth infections (Bobak DA. Curr Infect Dis Rep 2006; 8:91; Diaz E,&nbsp;et al. Am J Trop Med Hyg 2003; 68:384). It is effective against mild to moderate amebiasis, 500 mg bid x 3 d (Rossignol JF, et al. Trans R Soc Trop Med Hyg 2007; 101:1025; Escobedo AE,&nbsp;et al. Arch Dis Child 2009; 94:478). It is FDA-approved only for treatment of diarrhea caused by",
"         <em>",
"          Giardia",
"         </em>",
"         or",
"         <em>",
"          Cryptosporidium",
"         </em>",
"         (Med Lett Drugs Ther 2003; 45:29). Nitazoxanide is available in 500 mg tablets and an oral suspension; it should be taken with food.",
"        </li>",
"        <li>",
"         Safety of ivermectin in young children (&lt;15 kg) and pregnant women remains to be established. Ivermectin should be taken on an empty stomach with water (Fox NM. Curr Opin Infect Dis 2006; 19:588).",
"        </li>",
"        <li>",
"         No drug has been demonstrated to be effective. Albendazole 25 mg/kg/d PO x 20 d started as soon as possible (up to 3 d after possible infection) might prevent clinical disease and is recommended for children with known exposure (ingestion of raccoon stool or contaminated soil) (Murray WJ, Kazacos KR. Clin Infect Dis 2004; 39:1484). Mebendazole, levamisole or ivermectin could be tried if albendazole is not available. Steroid therapy may be helpful, especially in eye and CNS infections (Gavin PJ,&nbsp;et al. Clin Microbiol Rev 2005; 18:703). Ocular baylisascariasis has been treated successfully using laser photocoagulation therapy to destroy the intraretinal larvae (Garcia CA,&nbsp;et al. Eye (Lond) 2004; 18:624).",
"        </li>",
"        <li>",
"         Heukelbach J, Feldmeier H.&nbsp;Lancet Infect Dis 2008; 8:302.",
"        </li>",
"        <li>",
"         No drug is curative against",
"         <em>",
"          Dracunculus",
"         </em>",
"         . A program for monitoring local sources of drinking water to eliminate transmission has dramatically decreased the number of cases worldwide. The treatment of choice is slow extraction of worm combined with wound care and pain management (Morbid Mortal Wkly Rep 2009; 58:1123).",
"        </li>",
"        <li>",
"         Since family members are usually infected, treatment of the entire household is recommended; retreatment after 14 to 21 d may be needed.",
"        </li>",
"        <li>",
"         Pyrantel pamoate suspension can be mixed with milk or fruit juice.",
"        </li>",
"        <li>",
"         Antihistamines or corticosteroids may be required to decrease allergic reactions to components of disintegrating microfilariae that result from treatment, especially in infection caused by",
"         <em>",
"          Loa loa",
"         </em>",
"         .",
"        </li>",
"        <li>",
"         Endosymbiotic",
"         <em>",
"          Wolbachia",
"         </em>",
"         bacteria, which are present in most human filariae except",
"         <em>",
"          Loa loa",
"         </em>",
"         , are essential to filarial growth, development, embryogenesis, and survival and represent an additional target for therapy. Doxycycline 100 or 200 mg/d PO x 6 to 8 weeks in lymphatic filariasis, onchocerciasis, and",
"         <em>",
"          Mansonella perstans",
"         </em>",
"         has resulted in substantial loss of",
"         <em>",
"          Wolbachia",
"         </em>",
"         and decrease in both micro- and macrofilariae (Bockarie MJ,&nbsp;et al. Expert Rev Anti Infect Ther 2009; 7:595; Hoerauf A.&nbsp;Curr Opin Infect Dis 2008; 21:673; Coulibaly YI,&nbsp;et al. N Engl J Med 2009; 361:1448). Use of tetracyclines is contraindicated in pregnancy and in children &lt;8 yrs old.",
"        </li>",
"        <li>",
"         Most symptoms are caused by adult worm. A single-dose combination of albendazole (400 mg PO) with either ivermectin (200 mcg/kg PO) or diethylcarbamazine (6 mg/kg PO) is effective for reduction or suppression of",
"         <em>",
"          W. bancrofti",
"         </em>",
"         microfilaria; none of these drug combinations kills all the adult worms (Addiss D,&nbsp;et al. Cochrane Database Syst Rev 2004; CD003753).",
"        </li>",
"        <li>",
"         For patients with microfilaria in the blood, Medical Letter consultants start with a lower dosage and scale up: dose one: 50 mg; dose two: 50 mg tid; dose three: 100 mg tid; doses 4 to 14: 6 mg/kg/d in 3 doses (for",
"         <em>",
"          Loa Loa",
"         </em>",
"         doses 4 to 14: 9 mg/kg/d in 3 doses). Multi-dose regimens have been shown to provide more rapid reduction in microfilaria than single-dose diethylcarbamazine, but microfilaria levels are similar 6 to 12 months after treatment (Andrade LD,&nbsp;et al. Trans R Soc Trop Med Hyg 1995; 89:319; Simonsen PE,&nbsp;et al. Am J Trop Med Hyg 1995; 53:267). A single dose of 6 mg/kg is used in endemic areas for mass treatment, but there are no studies directly comparing the efficacy of the single-dose regimen to a 12-day course. It should be used cautiously in geographic regions where",
"         <em>",
"          O. volvulus",
"         </em>",
"         coexists with other filariae. One review concluded that the 12-day regimen did not have a higher macrofilaricidal effect than single dose (Hoerauf A.&nbsp;Curr Opin Infect Dis 2008; 21: 673; Figueredo- Silva J,&nbsp;et al. Trans R Soc Trop Med Hyg 1996; 90:192; Noroes J,&nbsp;et al. Trans R Soc Trop Med Hyg 1997; 91:78).",
"        </li>",
"        <li>",
"         Diethylcarbamazine should not be used for treatment of",
"         <em>",
"          Onchocerca volvulus",
"         </em>",
"         due to the risk of increased ocular side effects (including blindness) associated with rapid killing of the worms. It should be used cautiously in geographic regions where",
"         <em>",
"          O. volvulus",
"         </em>",
"         coexists with other filariae. Diethylcarbamazine is contraindicated during pregnancy. See also footnote 22.",
"        </li>",
"        <li>",
"         In heavy infections with",
"         <em>",
"          Loa loa",
"         </em>",
"         , rapid killing of microfilariae can provoke encephalopathy. Apheresis has been reported to be effective in lowering microfilarial counts in patients heavily infected with",
"         <em>",
"          Loa loa",
"         </em>",
"         (Ottesen EA.&nbsp;Infect Dis Clin North Am 1993; 7:619). Albendazole may be useful for treatment of loiasis when diethylcarbamazine is ineffective or cannot be used, but repeated courses may be necessary (Klion AD,&nbsp;et al. Clin Infect Dis 1999; 29:680; Tabi TE,&nbsp;et al. Am J Trop Med Hyg 2004; 71:211). Ivermectin has also been used to reduce microfilaremia, but albendazole is preferred because of its slower onset of action and lower risk of precipitating encephalopathy (Klion AD,&nbsp;et al. J Infect Dis 1993; 168:202; Kombila M, et al. Am J Trop Med Hyg 1998; 58:458). Diethylcarbamazine, 300 mg PO once/wk, has been recommended for prevention of loiasis (Nutman TB, et al. N Engl J Med 1988; 319:752).",
"        </li>",
"        <li>",
"         Diethylcarbamazine has no effect. A single dose of ivermectin 200 mcg/kg PO reduces microfilaria densities and provides both short- and long-term reductions in",
"         <em>",
"          M. ozzardi",
"         </em>",
"         microfilaremia (Gonzalez AA,&nbsp;et al. W Indian Med J 1999; 48:231).",
"        </li>",
"        <li>",
"         One small study compared single-dose ivermectin to albendazole alone or the two together although the combination reduced microfilaremia 1 and 3 months post treatment, the effect was not significant at 6 and 12 months (Asio SM,&nbsp;et al. Ann Trop Med Parasitol 2009; 103:31).",
"        </li>",
"        <li>",
"         Diethylcarbamazine is potentially curative due to activity against both adult worms and microfilariae. Ivermectin is active only against microfilariae.",
"        </li>",
"        <li>",
"         Vijayan VK. Curr Opin Pulm Med 2007; 13:428. Relapses occur and can be treated with a repeated course of diethylcarbamazine.",
"        </li>",
"        <li>",
"         Diethylcarbamazine should not be used for treatment of this disease because rapid killing of the worms can lead to blindness. Periodic treatment with ivermectin (every 3 to 12 months), 150 mcg/kg PO, can prevent blindness due to ocular onchocerciasis (Udall DN.&nbsp;Clin Infect Dis 2007; 44:53). Skin reactions after ivermectin treatment are often reported in persons with high microfilarial skin densities. Ivermectin has been inadvertently given to pregnant women during mass treatment programs; the rates of congenital abnormalities were similar in treated and untreated women. Because of the high risk of blindness from onchocerciasis, the use of ivermectin after the first trimester is considered acceptable according to the WHO. Addition of 6 to 8 weeks of doxycycline to ivermectin is increasingly common. Doxycycline (100 mg/day PO for 6 weeks), followed by a single 150 mcg/kg PO dose of ivermectin, resulted in up to 19 months of amicrofilaridermia and 100% elimination of",
"         <em>",
"          Wolbachia",
"         </em>",
"         species (Hoerauf A,&nbsp;et al. Lancet 2001; 357:1415).",
"        </li>",
"        <li>",
"         Marcos LA.&nbsp;Curr Opin Infect Dis 2008; 21:523.",
"        </li>",
"        <li>",
"         Praziquantel should be taken with liquids during a meal.",
"        </li>",
"        <li>",
"         Unlike infections with other flukes,",
"         <em>",
"          Fasciola hepatica",
"         </em>",
"         infections may not respond to praziquantel. Triclabendazole&nbsp;appears to be safe and effective, but data are limited (Keiser J,&nbsp;et al. Expert Opin Investig Drugs 2005; 14:1513). It is available from Victoria Pharmacy, Zurich, Switzerland (www.pharmaworld.com; 011-4143-344-60-60) and should be given with food for better absorption. Nitazoxanide also appears to have efficacy in treating fascioliasis in adults and in children (Favennec L,&nbsp;et al. Aliment Pharmacol Ther 2003; 17:265; Rossignol JF,&nbsp;et al. Trans R Soc Trop Med Hyg 1998; 92:103; Kabil SM,&nbsp;et al. Curr Ther Res 2000; 61:339).",
"        </li>",
"        <li>",
"         Keiser&nbsp;J,&nbsp;et al. Expert Opin Investig Drugs 2005; 14:1513. See footnote 25 for availability.",
"        </li>",
"        <li>",
"         All patients should be treated with medication whether surgery is attempted or not. Herman JS, Chiodini PL.&nbsp;Clin Microbiol Rev 2009; 22:484; Ramirez-Avila&nbsp;L,&nbsp;et al. Clin Infect Dis 2009; 48:322.",
"        </li>",
"        <li>",
"         Pasuralertsakul S,&nbsp;et al. Am Trop Med Parasitol 2008; 102:455; Molavi G, et al. J Helminth 2006; 80:425.",
"        </li>",
"        <li>",
"         Doenhoff MJ,&nbsp;et al. Curr Opin Infect Dis 2008; 21:659.",
"        </li>",
"        <li>",
"         Geographically restricted to Central Western Africa and the island of S&atilde;o Tom&eacute;. Usually a disease of the lower GI tract; there are also case reports of complications including central nervous system, liver, and cardiopulmonary involvement (Murinello A, et al. GE - J Port Gastrenterol 2006; 13:97).",
"        </li>",
"        <li>",
"         Oxamniquine, which is not available in the US, is generally not as effective as praziquantel. It has been useful, however, in some areas in which praziquantel is less effective (Ferrari ML,&nbsp;et al. Bull World Health Organ 2003; 81:190;&nbsp;Harder A. Parasitol Res 2002; 88:395). Oxamniquine is contraindicated in pregnancy. It should be taken after food.",
"        </li>",
"        <li>",
"         In East Africa, the dose should be increased to 30 mg/kg PO, and in Egypt and South Africa to 30 mg/kg/d PO x 2 d. Some experts recommend 40 to 60 mg/kg PO over 2 to 3 d in all of Africa (Shekhar&nbsp;KC.&nbsp;Drugs 1991; 42:379).",
"        </li>",
"        <li>",
"         In immunocompromised patients or disseminated disease, it may be necessary to prolong or repeat therapy, or to use other agents. Veterinary parenteral and enema formulations of ivermectin have been used in severely ill patients with hyperinfection who were unable to take or reliably absorb oral medications (Marty FM,&nbsp;et al. Clin Infect Dis 2005; 41:e5; Lichtenberger P,&nbsp;et al. Transpl Infect Dis 2009; 11:137). In disseminated strongyloidiasis, combination therapy with albendazole and ivermectin has been suggested (Seqarra&nbsp;M.&nbsp;Ann Pharmacother 2007; 41:1992).",
"        </li>",
"        <li>",
"         Niclosamide must be thoroughly chewed or crushed and swallowed with a small amount of water.",
"        </li>",
"        <li>",
"         Nitazoxanide may be an alternative (Ortiz JJ,&nbsp;et al. Trans R Soc Trop Med Hyg 2002; 96:193; Chero JC,&nbsp;et al. Trans R Soc Trop Med Hyg 2007; 101:203; Diaz E,&nbsp;et al. Am J Trop Med Hyg 2003; 68:384).",
"        </li>",
"        <li>",
"         Patients may benefit from surgical resection or percutaneous drainage of cysts. Praziquantel is useful preoperatively or in case of spillage of cyst contents during surgery. Percutaneous aspiration-injection-reaspiration (PAIR) with ultrasound guidance plus albendazole therapy has been effective for management of hepatic hydatid cyst disease (Moro P, Schantz PM.&nbsp;Int J Infect Dis 2009; 13:125).",
"        </li>",
"        <li>",
"         Surgical excision is the only reliable means of cure. Reports have suggested that in nonresectable cases use of albendazole (400 mg bid) can stabilize and sometimes cure infection (P Moro and PM Schantz, Int J Infect Dis 2009; 13:125).",
"        </li>",
"        <li>",
"         Advances in neuroimaging using CT and MRI have facilitated the ability to make an accurate diagnosis (White AC,&nbsp;Jr. J Infect Dis 2009; 199:1261). Initial therapy for patients with inflamed parenchymal cysticercosis should focus on symptomatic treatment with anti-seizure medication (Sinha S, Sharma BS.&nbsp;J Clin Neurosci 2009; 16:867). Patients with live parenchymal cysts who have seizures should be treated with albendazole together with steroids and an anti-seizure medication (Garcia HH,&nbsp;et al. N Engl J Med 2004; 350:249). Patients with subarachnoid cysts or giant cysts in the fissures should be treated for at least 30 d (Proa&ntilde;o JV,&nbsp;et al. N Engl J Med 2001; 345:879). Surgical intervention (especially neuroendoscopic removal) or CSF diversion followed by albendazole and steroids is indicated for obstructive hydocephalus. Arachnoiditis, vasculitis or cerebral edema is treated with albendazole or praziquantel plus prednisone (60 mg/d) or dexamethasone (4 to 6 mg/d). Any cysticercocidal drug may cause irreparable damage when used to treat ocular or spinal cysts, even when corticosteroids are used. An ophthalmic exam should always precede treatment to rule out intraocular cysts.",
"        </li>",
"        <li>",
"         Gottstein B,&nbsp;et al. Clin Microbiol Rev 2009; 22:127.",
"        </li>",
"        <li>",
"         Optimum duration of therapy is not known; some Medical Letter consultants would treat x 20 d. For severe symptoms or eye involvement, corticosteroids can be used in addition (Despommier D.&nbsp;Clin Microbiol Rev 2003; 16:265).",
"        </li>",
"       </ol>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, June 2010; Vol. 8 (suppl):e1-20. www.medicalletter.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29990=[""].join("\n");
var outline_f29_18_29990=null;
var title_f29_18_29991="Meckels diverticulitis";
var content_f29_18_29991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Meckels diverticulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The abdominal CT scan in this 82-year-old patient with Meckel's diverticulitis demonstrates an air-filled diverticulum (arrow) surrounded by significant induration (arrowhead). A stone is demonstrated within the diverticulum (dashed arrow).",
"    <div class=\"footnotes\">",
"     CT: computed tomography",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29991=[""].join("\n");
var outline_f29_18_29991=null;
var title_f29_18_29992="Causes, presentation, and evaluation of sellar masses";
var content_f29_18_29992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes, presentation, and evaluation of sellar masses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/18/29992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/18/29992/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/18/29992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/18/29992/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/18/29992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/18/29992/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/18/29992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sellar masses typically present in one or more ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With neurologic symptoms, such as visual impairment or headache",
"     </li>",
"     <li>",
"      As an incidental finding on magnetic resonance imaging (MRI) performed for some other reason",
"     </li>",
"     <li>",
"      With hormonal abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the causes, clinical manifestations, and evaluation of sellar masses. The clinical presentation and management of individual pituitary tumors and of hypopituitarism are discussed separately. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pituitary adenomas are the most common cause of sellar masses from the third decade on, accounting for up to 10 percent of all intracranial neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Other disorders, which are often difficult to distinguish from pituitary adenomas by imaging, include physiologic enlargement of the pituitary and benign and malignant tumors (",
"    <a class=\"graphic graphic_table graphicRef68108 \" href=\"UTD.htm?4/34/4652\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pituitary adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pituitary adenomas are benign tumors of the anterior pituitary, but they are true neoplasms, as shown by clonality studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Incidence and prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few population studies of the incidence and prevalence of pituitary adenomas. However, a population-based study in Northern Finland, where all patients within a health care district are referred to a predetermined medical center, found the following standardized",
"    <strong>",
"     incidence",
"    </strong>",
"    rates per 100,000 (cases diagnosed between 1992 and 2007) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All pituitary adenomas &ndash; 4.0",
"     </li>",
"     <li>",
"      Lactotroph adenomas &ndash; 2.2",
"     </li>",
"     <li>",
"      Clinically nonfunctioning adenomas &ndash; 1.0",
"     </li>",
"     <li>",
"      Somatotroph adenomas &ndash; 0.34",
"     </li>",
"     <li>",
"      Corticotroph adenomas &ndash; 0.17",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Past studies of pituitary adenomas in the population are thought to have underestimated their true prevalence. In a current report from a single community of over 80,000 inhabitants in England, the",
"    <strong>",
"     prevalence",
"    </strong>",
"    of pituitary adenomas per 100,000 was fourfold higher than previous estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All adenomas &ndash; 77.6",
"     </li>",
"     <li>",
"      Lactotroph adenomas &ndash; 44.4",
"     </li>",
"     <li>",
"      Nonfunctioning adenomas &ndash; 22.2",
"     </li>",
"     <li>",
"      Somatotroph adenomas &ndash; 8.6",
"     </li>",
"     <li>",
"      Corticotroph adenomas &ndash; 1.2",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the following genes may play a role in the development of one or more types of pituitary tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MEN1 &ndash; Loss of function mutations of this tumor suppressor gene appear to be responsible for the tumors that occur in the parathyroids, pancreatic islets, and pituitary glands of patients who have multiple endocrine neoplasia type 1 syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/8\">",
"       8",
"      </a>",
"      ]. However, mutations in this gene do not appear to cause sporadic pituitary adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gs-alpha &ndash; An activating mutation of the alpha subunit of the guanine nucleotide stimulatory protein (Gs-alpha) gene is found in approximately 40 percent of somatotroph adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. These mutations result in constitutive activation of adenylyl cyclase, which may play a role in both cell division and excessive growth hormone secretion by these adenomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"       \"Causes and clinical manifestations of acromegaly\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PTTG &ndash; The pituitary tumor transforming gene, which was cloned from a rat pituitary tumor cell line, is overexpressed in most human pituitary adenomas compared with nonadenomatous pituitary tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FGF receptor-4 &ndash; A truncated form of the receptor for fibroblast growth factor-4 has been identified in human pituitary adenomas. Transgenic mice that express this mutation in their lactotroph cells develop lactotroph adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomas are classified by size and the cell of origin. Lesions smaller than 1 cm are classified as microadenomas, and lesions larger than 1 cm are classified as macroadenomas. The tumors can arise from any type of cell of the anterior pituitary and may result in increased secretion of the hormone(s) produced by that cell",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased secretion of other hormones due to compression of other cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonadotroph adenomas usually present as clinically nonfunctioning sellar masses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyrotroph adenomas may present as clinically nonfunctioning sellar masses that secrete only alpha or TSH-B subunits or may cause hyperthyroidism due to increased secretion of intact thyroid stimulating hormone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link&amp;anchor=H9#H9\">",
"       \"Disorders that cause hyperthyroidism\", section on 'TSH-mediated hyperthyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Corticotroph adenomas usually cause Cushing's disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"       \"Establishing the cause of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lactotroph adenomas usually cause hyperprolactinemia, which leads to hypogonadism in women and men. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Somatotroph adenomas typically cause acromegaly due to increased growth hormone secretion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"       \"Causes and clinical manifestations of acromegaly\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Lactotroph/somatotroph",
"      </span>",
"      adenoma combinations that secrete both prolactin and growth hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/16\">",
"       16",
"      </a>",
"      ] are well recognized and cause the clinical syndromes of both hormones. Other mixed cell adenomas, sometimes called plurihormonal adenomas, can involve any combination of cells, but are uncommon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pituitary hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several recognized causes of hyperplasia of the pituitary. These may present as sellar masses and be misdiagnosed as pituitary adenomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactotroph hyperplasia during pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thyrotroph and gonadotroph hyperplasia due to long-standing primary hypothyroidism and primary hypogonadism, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/17-21\">",
"       17-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Somatotroph hyperplasia due to ectopic secretion of growth hormone-releasing hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other benign tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other benign tumors can occur in or near the sella, including craniopharyngiomas, meningiomas, and less commonly, pituicytomas.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Craniopharyngioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniopharyngiomas are solid or mixed solid-cystic benign tumors that arise from remnants of Rathke's pouch along a line from the nasopharynx to the diencephalon. Most are either intrasellar or suprasellar. About 50 percent present clinically during childhood and adolescence, the other 50 percent present after age 20, some not until age 70 or 80. The major presenting symptoms are growth retardation in children and abnormal vision in adults. In addition, pituitary hormonal deficiencies, including diabetes insipidus, are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"     \"Craniopharyngioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Meningioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meningioma is a usually benign tumor arising from the meninges anywhere within the head. Some arise near the sella, causing visual impairment and hormonal deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link\">",
"     \"Meningioma: Clinical presentation and diagnosis\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691693\">",
"    <span class=\"h3\">",
"     Pituicytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is an uncommon, low-grade (WHO grade 1), indolent glioma arising from the pituicytes of the posterior pituitary. It presents as a sellar mass, which is usually mistaken for a pituitary adenoma, and has no known hormonal secretory function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Malignant tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some malignant tumors arise within or near the sella, and others metastasize to this site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies that arise in the parasellar region include germ cell tumors, sarcomas, chordomas, and lymphomas. Pituitary carcinomas are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Germ cell tumors &ndash; Germ cell tumors, also called ectopic pinealomas, usually occur through the third decade of life and may present with headache, nausea, vomiting, and lethargy (from increased intracranial pressure in patients with pineal lesions), diplopia, hypopituitarism or diabetes insipidus (with suprasellar tumors), and paralysis of upward conjugate gaze (Parinaud's syndrome). Imaging shows a mass in the third ventricle and serum concentrations of human chorionic gonadotropin-beta (B-hCG),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alpha fetoprotein (AFP) may be increased. Although these lesions are highly malignant and metastasize readily, they are also highly radiosensitive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"       \"Pediatric intracranial germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chordomas &ndash; Chordomas usually are locally aggressive tumors that can metastasize. They often arise in the clivus and present with headaches, visual impairment, and anterior pituitary hormonal deficiencies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=see_link&amp;anchor=H16#H16\">",
"       \"Chordoma and chondrosarcoma of the skull base\", section on 'Chordoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary lymphoma &ndash; Primary central nervous system (CNS) lymphoma, which sometimes involve the pituitary and hypothalamus, is an intracranial neoplasm that is being recognized with increasing frequency. A review of 13 patients with pituitary involvement noted neurologic symptoms (headaches and visual and oculomotor impairment)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deficiencies of anterior pituitary hormones and antidiuretic hormone&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/24\">",
"       24",
"      </a>",
"      ]. MRI shows a sellar mass with variable extrasellar extension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastases to the hypothalamus and pituitary gland account for 1 to 2 percent of sellar masses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. They occur most commonly with breast cancer in women and lung cancer in men, but can be seen with many other cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Symptoms, which occur in approximately 7 percent of patients, include diabetes insipidus, anterior pituitary dysfunction, visual field defects, retroorbital pain, and ophthalmoplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/25\">",
"     25",
"    </a>",
"    ]. Survival in 36 patients in one series averaged six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rathke's cleft, arachnoid, and dermoid cysts can produce sellar enlargement, possibly resulting in visual impairment, diabetes insipidus, anterior pituitary hormonal deficiencies, and hydrocephalus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"     \"Craniopharyngioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pituitary abscesses, which are rare, can occur in a normal or diseased pituitary gland. In a series of 24 patients, 16 (33 percent) presented with symptoms and physical findings consistent with a pituitary mass, while only eight had features suggestive of infection (fever, leukocytosis, meningismus) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/28\">",
"     28",
"    </a>",
"    ]. Imaging studies including CT and MRI were unable to distinguish between pituitary abscess and pituitary adenoma. As a result, most patients were diagnosed at the time of surgical exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Arteriovenous fistula of the cavernous sinus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous fistulae of the cavernous sinus can cause modest enlargement of the pituitary gland. Pituitary size returns toward baseline after the fistula is blocked [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypophysitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of hypophysitis can enlarge the pituitary early in their course. Lymphocytic infiltration of the pituitary usually occurs in late pregnancy or the postpartum period, but can also be seen in women at other times and infrequently in men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/30\">",
"     30",
"    </a>",
"    ] and increasingly due to anti-CTLA-4 treatment of malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. It is characterized by headaches of an intensity out of proportion to the size of the lesion and hypopituitarism, in which adrenal insufficiency is unusually prominent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H9#H9\">",
"     \"Causes of hypopituitarism\", section on 'Hypophysitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sellar masses can present with neurologic symptoms, abnormalities related to undersecretion or oversecretion of pituitary hormones, or as an incidental finding on radiologic examination performed for some other reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Visual defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired vision is the most common symptom that leads a patient with a nonfunctioning adenoma, of which over 80 percent are gonadotroph adenomas, to seek medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visual impairment is caused by suprasellar extension of the adenoma, leading to compression of the optic chiasm. The most common complaint is diminished vision in the temporal fields (bitemporal hemianopsia). One or both eyes may be affected and, if both, to variable degrees. Diminished visual acuity occurs when the optic chiasm is more severely compressed. Other patterns of visual loss can also occur. Thus, an intrasellar lesion should be suspected when there is any unexplained pattern of visual loss.",
"   </p>",
"   <p>",
"    The onset of the visual deficit is usually so gradual that many patients do not seek ophthalmologic consultation for months or even years. Even at this time, the reason for the deficit may not be recognized, unless a visual field examination is performed, further delaying the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neurologic symptoms that may cause a patient with a sellar mass to seek medical attention include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headaches, presumably caused by expansion of the sella. The quality of the headache is not specific.",
"     </li>",
"     <li>",
"      Diplopia, induced by oculomotor nerve compression resulting from lateral extension of the adenoma.",
"     </li>",
"     <li>",
"      Pituitary apoplexy induced by sudden hemorrhage into the adenoma, causing excruciating headache and diplopia.",
"     </li>",
"     <li>",
"      Cerebrospinal fluid rhinorrhea, caused by inferior extension of the adenoma, an extremely uncommon presentation.",
"     </li>",
"     <li>",
"      Parinaud syndrome, a constellation of neuroophthalmologic findings, most often paralysis of upward conjugate gaze, that result from ectopic pinealomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link&amp;anchor=H9#H9\">",
"       \"Supranuclear disorders of gaze in children\", section on 'Parinaud syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hormone deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of initial presentation with a neurologic symptom, many patients with sellar masses, when carefully questioned, admit to symptoms of pituitary hormone deficiencies. However, these symptoms are not usually the reason that the patient seeks medical attention.",
"   </p>",
"   <p>",
"    The most common pituitary hormone deficiencies are of gonadotropins, resulting in hypogonadism in both men and women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EVALUATION OF A SELLAR MASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sellar masses should be evaluated both radiologically and hormonally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Radiologic procedures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the single best imaging procedure for most sellar masses, and there is usually no need to perform any other imaging study. Certain MRI findings suggest a greater likelihood of some kinds of sellar masses than others [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/35\">",
"     35",
"    </a>",
"    ]. As an example, a mass that is separate from the pituitary gland generally indicates that the mass is not a pituitary adenoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56435 \" href=\"UTD.htm?32/14/32994\">",
"     image 1",
"    </a>",
"    ). However, no finding is usually pathognomonic of any one kind of mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63618 \" href=\"UTD.htm?10/54/11107\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600539362\">",
"    <span class=\"h4\">",
"     Unenhanced image",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pituitary tissue and most sellar lesions, pituitary adenomas, and other tumors, have a signal that is similar to or slightly greater in intensity than that of central nervous system tissue. Cystic lesions, such as Rathke's cleft cysts, often have a low intensity signal on T1-weighted images; however, craniopharyngiomas and even pituitary adenomas may be partially cystic and, therefore, have low intensity signals. Furthermore, the signal intensity on T1-weighted images will be high if the protein or lipid concentration of the cyst fluid is high. On T2-weighted images, cystic lesions may have a high intensity signal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76412 \" href=\"UTD.htm?8/52/9027\">",
"     image 3",
"    </a>",
"    ). Hemorrhage into the pituitary gland results in a high intensity signal on both T1- and T2-weighted images.",
"   </p>",
"   <p>",
"    Meningiomas typically have a brighter and more homogeneous signal than pituitary adenomas. They also have a suprasellar rather than a sellar epicenter and a dural-based attachment best seen after contrast enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600539373\">",
"    <span class=\"h4\">",
"     Gadolinium-enhanced image",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pituitary tissue takes up gadolinium to a greater degree than CNS tissue and therefore has a higher intensity signal than the surrounding CNS. Both micro- and macroadenomas of the pituitary (as well as other sellar masses such as craniopharyngiomas and meningiomas) usually take up gadolinium to a lesser degree than the normal pituitary but more than the CNS. Therefore, the degree of gadolinium enhancement does not distinguish one kind of sellar mass from another. The postcontrast enhancement of meningiomas is usually homogeneous. If a sellar lesion can be seen as separate from the normal pituitary, whether on unenhanced or, more commonly, enhanced images, the lesion is not a pituitary adenoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56435 \" href=\"UTD.htm?32/14/32994\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among patients with moderate to advanced renal failure (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should be avoided if possible. This issue, as well as the role of hemodialysis after the procedure if gadolinium-based imaging must be performed, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcification in a craniopharyngioma or meningioma is seen better by CT scan than by MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70146 \" href=\"UTD.htm?34/50/35631\">",
"     image 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"     \"Craniopharyngioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hormonal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothalamic-pituitary hormonal function should be evaluated whenever a sellar mass is encountered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Hormonal hypersecretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersecretion, with the exception noted below, is caused only by pituitary adenomas. As a result, the demonstration of hormonal hypersecretion identifies both the sellar mass as a pituitary adenoma and the kind of adenoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A serum prolactin concentration &gt;200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      generally identifies a lactotroph adenoma; values that are between 20 and 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      could be due to a lactotroph adenoma or to any other sellar mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of hyperprolactinemia\", section on 'Serum prolactin concentration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The best",
"      <strong>",
"       single",
"      </strong>",
"      test for the diagnosis of acromegaly is measurement of serum insulin-like growth factor (IGF)-1. Among patients with equivocal values, serum growth hormone levels can be measured after an oral glucose load. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link\">",
"       \"Diagnosis of acromegaly\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated 24-hour urine cortisol excretion associated with a high-normal or high ACTH concentration usually indicates a corticotroph adenoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"       \"Establishing the diagnosis of Cushing's syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"       \"Establishing the cause of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gonadotroph adenomas can be identified by characteristic patterns of basal and TRH-stimulated concentrations of gonadotropins and their subunits; these patterns differ somewhat in men and women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas\"",
"      </a>",
"      .) TRH is not currently available in the United States but is still available in many other countries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thyrotroph adenomas are characterized by a clinically hyperthyroid patient who has a diffuse goiter and elevations in serum FT4 and T3, but an inappropriately normal or elevated serum TSH level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hormonal hyposecretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal hyposecretion can be caused by any hypothalamic or pituitary lesion and therefore usually has no value in the differential diagnosis of a sellar mass. One exception to this statement is that the spontaneous development of central diabetes insipidus indicates that the lesion affects the hypothalamus or the stalk and is therefore",
"    <strong>",
"     not a pituitary lesion",
"    </strong>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not generally useful in the differential diagnosis of a sellar mass, the possibility of hormonal hyposecretion should be evaluated in all patients who have a sellar mass in order to identify and replace hormone deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pituitary incidentaloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of the evaluation in a patient with an incidentally discovered intrasellar MRI signal abnormality depends upon its size. If it is larger than 10 mm, it should be evaluated as described above. If the mass is smaller than 10 mm, especially much smaller, and the patient has no clinical findings of pituitary dysfunction, we usually measure only the serum prolactin concentration which, in one report, was much more cost-effective than either measurement of multiple hormones or performance of follow-up MRIs at 6 and 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29992/abstract/37\">",
"     37",
"    </a>",
"    ]. One exception may be the patient who is quite anxious about the presence of a small pituitary tumor. No evaluation for hormonal hyposecretion or visual abnormalities is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12981?source=see_link\">",
"     \"Incidentally discovered sellar masses (pituitary incidentalomas)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=see_link\">",
"       \"Patient information: Prolactinoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=see_link\">",
"       \"Patient information: Pituitary adenoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=see_link\">",
"       \"Patient information: High prolactin levels and prolactinomas (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=see_link\">",
"       \"Patient information: Acromegaly (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=see_link\">",
"       \"Patient information: Meningioma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Causes and presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sellar masses usually present with neurologic symptoms, hormonal abnormalities, or as an incidental finding on MRI. Pituitary adenomas are the most common cause of sellar masses, but other causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic enlargement of the pituitary, most commonly during pregnancy but also in primary hypothyroidism and primary hypogonadism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other benign tumors, such as craniopharyngioma and meningioma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"       \"Craniopharyngioma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link\">",
"       \"Meningioma: Clinical presentation and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignant tumors, both primary (germ cell tumor, chordoma, primary CNS lymphoma), and metastatic (most commonly from breast and lung cancer). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"       \"Pediatric intracranial germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=see_link&amp;anchor=H16#H16\">",
"       \"Chordoma and chondrosarcoma of the skull base\", section on 'Chordoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sellar masses may also be due to a cyst, abscess, or arteriovenous fistula of the cavernous sinus. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cysts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Abscess'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Arteriovenous fistula of the cavernous sinus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypophysitis, especially lymphocytic (lymphocytic infiltration of the pituitary), occurs most commonly in postpartum women, but can also be seen in women at other times, and rarely in men, but increasingly due to anti-CTLA-4 treatment of malignancies. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hypophysitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend magnetic resonance imaging (MRI) as the single best, and usually only, imaging procedure for most sellar masses. Certain MRI findings suggest a greater likelihood of some kinds of sellar masses than others. As an example, finding a mass that is separate from the pituitary gland generally indicates that the mass is not a pituitary adenoma.",
"     </li>",
"     <li>",
"      We recommend evaluation of hypothalamic-pituitary hormonal function whenever a sellar mass is encountered. Hormonal hypersecretion is caused only by pituitary adenomas. Consequently, the demonstration of hormonal hypersecretion identifies the sellar mass as a pituitary adenoma and also identifies the type of adenoma. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Hormonal evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of the evaluation in a patient with an incidentally discovered intrasellar MRI signal abnormality (pituitary incidentaloma) depends upon its size. If it is larger than 10 mm, we recommend the hormonal evaluation as described above. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Hormonal evaluation'",
"      </a>",
"      above.) If it is smaller than 10 mm and the patient has no clinical findings of pituitary dysfunction, we recommend measuring only the serum prolactin concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12981?source=see_link\">",
"       \"Incidentally discovered sellar masses (pituitary incidentalomas)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hormonal hyposecretion may be caused by any hypothalamic or pituitary lesion and therefore usually has no value in the differential diagnosis of a sellar mass. One exception to this statement is that the spontaneous development of central diabetes insipidus indicates that the lesion affects the hypothalamus or the stalk and is therefore",
"      <strong>",
"       not a pituitary lesion.",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/1\">",
"      Gsponer J, De Tribolet N, D&eacute;ruaz JP, et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 1999; 78:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/2\">",
"      Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999; 28:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/3\">",
"      Saeger W, L&uuml;decke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007; 156:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/4\">",
"      Alexander JM, Biller BM, Bikkal H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990; 86:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/5\">",
"      Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/6\">",
"      Raappana A, Koivukangas J, Ebeling T, Piril&auml; T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010; 95:4268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/7\">",
"      Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/8\">",
"      Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998; 62:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/9\">",
"      Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A 2001; 98:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/10\">",
"      Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/11\">",
"      Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/12\">",
"      Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/13\">",
"      Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007; 28:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/14\">",
"      Ezzat S, Zheng L, Zhu XF, et al. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002; 109:69.",
"     </a>",
"    </li>",
"    <li>",
"     Snyder PJ. Gonadotroph adenomas. In: Endocrinology, DeGroot LJ (Ed), WB Saunders, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/16\">",
"      Bassetti M, Spada A, Arosio M, et al. Morphological studies on mixed growth hormone (GH)- and prolactin (PRL)-secreting human pituitary adenomas. Coexistence of GH and PRL in the same secretory granule. J Clin Endocrinol Metab 1986; 62:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/17\">",
"      Shimono T, Hatabu H, Kasagi K, et al. Rapid progression of pituitary hyperplasia in humans with primary hypothyroidism: demonstration with MR imaging. Radiology 1999; 213:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/18\">",
"      Alkhani AM, Cusimano M, Kovacs K, et al. Cytology of pituitary thyrotroph hyperplasia in protracted primary hypothyroidism. Pituitary 1999; 1:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/19\">",
"      Groff TR, Shulkin BL, Utiger RD, Talbert LM. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol 1984; 63:86S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/20\">",
"      Samaan NA, Stepanas AV, Danziger J, Trujillo J. Reactive pituitary abnormalities in patients with Klinefelter's and Turner's syndromes. Arch Intern Med 1979; 139:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/21\">",
"      Scheithauer BW, Moschopulos M, Kovacs K, et al. The pituitary in klinefelter syndrome. Endocr Pathol 2005; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/22\">",
"      Ezzat S, Asa SL, Stefaneanu L, et al. Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. J Clin Endocrinol Metab 1994; 78:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/23\">",
"      Ragel BT, Couldwell WT. Pituitary carcinoma: a review of the literature. Neurosurg Focus 2004; 16:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/24\">",
"      Giustina A, Gola M, Doga M, Rosei EA. Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity. J Clin Endocrinol Metab 2001; 86:4567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/25\">",
"      Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus 2004; 16:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/26\">",
"      Schubiger O, Haller D. Metastases to the pituitary--hypothalamic axis. An MR study of 7 symptomatic patients. Neuroradiology 1992; 34:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/27\">",
"      Morita A, Meyer FB, Laws ER Jr. Symptomatic pituitary metastases. J Neurosurg 1998; 89:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/28\">",
"      Vates GE, Berger MS, Wilson CB. Diagnosis and management of pituitary abscess: a review of twenty-four cases. J Neurosurg 2001; 95:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/29\">",
"      Sato N, Putman CM, Chaloupka JC, et al. Pituitary gland enlargement secondary to dural arteriovenous fistula in the cavernous sinus: appearance at MR imaging. Radiology 1997; 203:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/30\">",
"      Thodou E, Asa SL, Kontogeorgos G, et al. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995; 80:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/31\">",
"      Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/32\">",
"      Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/33\">",
"      Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15:6267.",
"     </a>",
"    </li>",
"    <li>",
"     Snyder PJ. Gonadotroph adenomas. In: The Pituitary, 2nd, Melmed S (Ed), Blackwell Science Inc., Malden, MA 2002. p.575.",
"    </li>",
"    <li>",
"     Pressman BD. Pituitary imaging. In: The Pituitary, 2nd, Melmed S (Ed), Blackwell Science Inc., Malden, MA 2002. p.663.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/36\">",
"      Taylor SL, Barakos JA, Harsh GR 4th, Wilson CB. Magnetic resonance imaging of tuberculum sellae meningiomas: preventing preoperative misdiagnosis as pituitary macroadenoma. Neurosurgery 1992; 31:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29992/abstract/37\">",
"      King JT Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab 1997; 82:3625.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6632 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29992=[""].join("\n");
var outline_f29_18_29992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Incidence and prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pituitary hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other benign tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Craniopharyngioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Meningioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691693\">",
"      - Pituicytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Malignant tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Primary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Arteriovenous fistula of the cavernous sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypophysitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Visual defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hormone deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EVALUATION OF A SELLAR MASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Radiologic procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H600539362\">",
"      Unenhanced image",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H600539373\">",
"      Gadolinium-enhanced image",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hormonal evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Hormonal hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hormonal hyposecretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pituitary incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Causes and presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6632|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/14/32994\" title=\"diagnostic image 1\">",
"      Sellar mass MRI III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/54/11107\" title=\"diagnostic image 2\">",
"      Sellar mass MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/52/9027\" title=\"diagnostic image 3\">",
"      Sellar mass MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/50/35631\" title=\"diagnostic image 4\">",
"      Craniopharyngioma CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/34/4652\" title=\"table 1\">",
"      Causes of sellar masses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=related_link\">",
"      Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=related_link\">",
"      Craniopharyngioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=related_link\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12981?source=related_link\">",
"      Incidentally discovered sellar masses (pituitary incidentalomas)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=related_link\">",
"      Patient information: Acromegaly (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=related_link\">",
"      Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=related_link\">",
"      Patient information: Meningioma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=related_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=related_link\">",
"      Patient information: Prolactinoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=related_link\">",
"      Pediatric intracranial germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_18_29993="Treatment of co-occurring anxiety disorders and substance use disorders";
var content_f29_18_29993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of co-occurring anxiety disorders and substance use disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/18/29993/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/18/29993/contributors\">",
"     Sudie Back, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/18/29993/contributors\">",
"     Megan M Moran-Santa Maria, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/18/29993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/18/29993/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/18/29993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/18/29993/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/18/29993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H553244\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety disorders and substance use disorders (SUDs) commonly co-occur [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The association between these disorders is multifaceted. Anxiety disorders may increase the risk for the development of SUDs, and may alter the presentation and treatment outcome of SUDs. SUDs may alter the presentation and outcome of treatment for anxiety disorders.",
"   </p>",
"   <p>",
"    The complexity of these comorbidities highlights the importance of a comprehensive understanding of symptoms of each disorder, proper diagnosis, and use of effective treatments, as well as consideration of potentially toxic drug-drug interactions, medication abuse liability, and patient adherence.",
"   </p>",
"   <p>",
"    This topic reviews treatment of co-occurring anxiety disorders and SUDs. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of co-occurring anxiety disorders and SUDs are described separately. Treatment of individual, noncomorbid anxiety disorders are described separately. Treatment of individual, noncomorbid SUDs are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=see_link\">",
"     \"Psychotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link\">",
"     \"Psychotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=see_link\">",
"     \"Pharmacotherapy for social anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31122064\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have identified medications and psychotherapies that effectively treat individual, noncomorbid anxiety disorders as well as individual, noncomorbid substance use disorders (SUDs). However, evidence from clinical trials, described below, is generally inadequate to determine the effectiveness of these interventions in treating co-occurring anxiety disorders and SUDs.",
"   </p>",
"   <p>",
"    Treating the SUD without addressing the anxiety disorder may render the patient vulnerable to relapse in the face of anxiety symptoms. Treating the anxiety disorder without addressing and monitoring the SUD will likely result in ineffective treatment. Anxiety symptoms may undermine treatment outcome by serving as a trigger for relapse. SUD patients need to learn skills for managing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    accepting anxiety symptoms without using substances. As an example, patients with panic disorder who complete exposure or other anxiety-provoking homework assignments while under the influence of alcohol or drugs will not experience the rise and fall of anxiety during those assignments, nor will they learn that they are able to withstand the anxiety without using alcohol or drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1332692\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrated cognitive-behavioral therapy (CBT) has been developed to treat both anxiety disorders and substance use disorders (SUDs) when the two disorders co-occur [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/4\">",
"     4",
"    </a>",
"    ]. Integrative CBT is comprised of cognitive and behavioral interventions that have been found to be effective for noncomorbid anxiety disorders and SUDs individually. The therapy can be used for co-occurring disorders in combination with or as an alternative to pharmacotherapy. (See",
"    <a class=\"local\" href=\"#H1332646\">",
"     'Integrated cognitive behavioral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evidence in support of integrated CBT for specific, co-occurring anxiety and substance use disorders is limited and has yielded mixed results (described below). However, based on these data, clinical trials of CBT for noncomorbid anxiety disorders or SUDs, and our clinical experience, we suggest first-line treatment of most patients with a co-occurring anxiety disorder and SUD with integrative CBT that addresses both disorders.",
"   </p>",
"   <p>",
"    For patients who prefer medication treatment rather than CBT, or if CBT is unavailable, we suggest treatment of the anxiety disorder with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) over other medications. In such cases, the SUD should be treated as well. Information on the pharmacotherapy of anxiety disorders and the treatment of SUDs is discussed is separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=see_link\">",
"     \"Pharmacotherapy for social anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest combined treatment with integrated CBT and an SSRI or SNRI rather than either intervention as monotherapy in patients with a co-occurring anxiety disorder and an SUD under the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the patient's anxiety disorder has previously responded to treatment with a serotonergic antidepressant",
"     </li>",
"     <li>",
"      If the anxiety disorder is severe and disabling",
"     </li>",
"     <li>",
"      If the disorders are accompanied by other comorbidities (eg, depression)",
"     </li>",
"     <li>",
"      If the disorders fail to respond adequately to treatment with either modality as monotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other medications are used to treat anxiety disorders that do not adequately respond to",
"    <span class=\"nowrap\">",
"     SSRIs/SNRIs,",
"    </span>",
"    and to treat SUDs. Selection of medications for treatment of co-occurring anxiety and substance-use disorders needs to take into account the abuse potential of medications prescribed as well as the potential for toxic interactions between the medications and abused substances, and between the medications and medical conditions caused by abused substances. In addition, clinicians should pro-actively address the increased risk of nonadherence to prescribed medications seen in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H250491208\">",
"     'Medication issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Medication may be needed early on particularly to help reduce anxiety symptoms while the patient is mastering behavioral ways of coping with anxiety, if there are withdrawal symptoms that will lead to relapse, and to help increase retention. Pharmacotherapies that address substance use withdrawal and craving, which may mimic or exacerbate anxiety symptoms, may be needed in addition to integrated CBT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192449\">",
"    <span class=\"h2\">",
"     Treatment initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating research evidence has challenged past beliefs that patients with a co-occurring anxiety disorder and SUD had to be abstinent for an extended period (eg, three to six months) before treating anxiety. As an example, in regard to posttraumatic stress disorder (PTSD), trials have found that addressing the trauma early in treatment results in significant improvements in anxiety symptoms as well as alcohol and drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In our clinical work with outpatients with an anxiety disorder and an SUD, we have increasingly shifted to initiating treatment upon their presentation to treatment, unless hospitalization is needed for a medically supervised detoxification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1332646\">",
"    <span class=\"h1\">",
"     INTEGRATED COGNITIVE BEHAVIORAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrated cognitive-behavioral therapy (CBT) combines cognitive and behavioral interventions for both anxiety disorders and co-occurring substance use disorders (SUDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/4\">",
"     4",
"    </a>",
"    ]. The components of integrative CBT in these disorders have varied in published trials, but typically include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Education and coping skills training for both disorders",
"     </li>",
"     <li>",
"      Exposure or other behavioral interventions for the anxiety disorder",
"     </li>",
"     <li>",
"      Relapse prevention for SUDs in patients who have achieved abstinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, clinical trials of integrated CBT for co-occurring anxiety disorders and SUDs (described below) have shown mixed results compared to treatment as usual or active interventions addressing one of the two comorbid disorders. Larger randomized trials are needed comparing monotherapy to integrative or sequential treatments, including medications, CBT, and other psychotherapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373135\">",
"    <span class=\"h1\">",
"     EFFICACY OF TREATMENTS FOR SPECIFIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings from clinical trials of psychotherapy and pharmacotherapy in patients with specific anxiety disorders and co-occurring substance use disorders (SUDs) are described here. Treatments with efficacy in these disorders when presenting without a co-occurring disorder are also briefly described and linked to topics with more detailed information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31122071\">",
"    <span class=\"h2\">",
"     Posttraumatic stress disorder",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H980721\">",
"    <span class=\"h3\">",
"     Integrated CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized and uncontrolled trials have found mixed results for various integrated CBT interventions in co-occurring posttraumatic stress disorder (PTSD) and SUDs, including cognitive-behavioral therapy (CBT) with and without exposure therapy for PTSD.",
"   </p>",
"   <p>",
"    Seeking Safety, a manualized, integrative group CBT, developed to treat co-occurring PTSD and SUDs, provides psychoeducation and teaches coping skills. Three randomized trials in women with PTSD and SUDs found mixed evidence of efficacy for the Seeking Safety intervention in conjunction with patients&rsquo; usual treatment compared to treatment as usual. No difference was found in PTSD or SUD symptom reduction between Seeking Safety and two other active treatments: a health education group and a group CBT addressing only SUDs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomly assigned 107 women with PTSD and an SUD to one of the following: group CBT addressing both disorders, another manualized, group CBT that addressed only substance abuse, or to treatment as usual [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/9\">",
"       9",
"      </a>",
"      ]. After three months of treatment, patients receiving either of the CBT interventions experienced reductions in substance use and in PTSD symptoms compared to patients receiving treatment as usual. Improvements were sustained at six and nine months. No differences were seen between the two CBT interventions.",
"     </li>",
"     <li>",
"      A trial randomly assigned 33 adolescent girls with PTSD and an SUD to group CBT addressing both disorders or to treatment as usual [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/10\">",
"       10",
"      </a>",
"      ]. After three months, group CBT led to reduced substance use compared to treatment as usual. No differences between group CBT and treatment as usual were seen on overall PTSD symptoms, but group CBT led to greater improvement on two of six subscales of an instrument measuring trauma-related symptoms.",
"     </li>",
"     <li>",
"      A trial randomly assigned 49 incarcerated women with PTSD and an SUD to either group CBT addressing both disorders or treatment as usual alone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/11\">",
"       11",
"      </a>",
"      ]. Following 18 to 20 weeks of treatment, both groups experienced reduction in PTSD symptoms and substance use, but no differences were seen between patients receiving group CBT compared to patients receiving treatment as usual.",
"     </li>",
"     <li>",
"      A clinical trial randomly assigned 353 women with PTSD and an SUD to receive 12 sessions of either group CBT addressing both disorders, or a health education group [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/12\">",
"       12",
"      </a>",
"      ]. Participants attended approximately half of the scheduled sessions: Seeking Safety (median = 6.2 sessions) and education (median = 6.2 sessions). Large reductions in PTSD symptoms and no change in substance use were seen over the course of treatment; no significant differences were seen between treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two uncontrolled trials and one controlled trial in patients with co-occurring PTSD and an SUD found mixed results for interventions integrating exposure therapy for PTSD and",
"    <span class=\"nowrap\">",
"     cognitive/behavioral",
"    </span>",
"    psychotherapy for the SUD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled trial of COPE (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure), 39 patients with co-occurring PTSD and cocaine dependence were enrolled in a 16-session, manual-guided psychotherapy that consisted of imaginal and in-vivo exposure therapy to treat PTSD and cognitive-behavioral techniques to treat cocaine dependence [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/13\">",
"       13",
"      </a>",
"      ]. An intent-to-treat analysis was not performed. A low participation rate was observed (only 15 of 39 patients attended at least 10 sessions). These 15 patients experienced a significant reduction in PTSD symptoms and cocaine use.",
"     </li>",
"     <li>",
"      A randomized trial compared COPE plus standard treatment for SUD to standard treatment for SUD alone in 103 patients with PTSD and substance dependence [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/7\">",
"       7",
"      </a>",
"      ]. COPE consisted of 12 sessions of psychotherapy, including imaginal and in-vivo exposure, as well as CBT for alcohol and drug use disorders. At nine months from the initiation of treatment, patients receiving COPE plus standard treatment experienced a greater mean decrease in PTSD symptom severity compared to patients receiving standard treatment alone (mean difference, &minus;38.24 versus &minus;22.14 on the Clinician-Administered PTSD Scale). No difference was seen in the severity of patients&rsquo; substance dependence.",
"     </li>",
"     <li>",
"      Substance Dependence PTSD Therapy (SDPT) is a five-month, twice-weekly, manualized individual cognitive-behavioral therapy utilizing relapse prevention and coping skills training for substance abuse, and psychoeducation, stress inoculation training, and in vivo exposure for PTSD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/14\">",
"       14",
"      </a>",
"      ]. A randomized trial comparing SDPT to Twelve-Step Facilitation Therapy in the treatment of an SUD was conducted among 19 patients with cocaine abuse and PTSD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/15\">",
"       15",
"      </a>",
"      ]. No statistically significant difference was seen between treatment groups on outcomes of substance abuse or PTSD symptoms. Retention in treatment was significantly better in the SDPT group than in the Twelve-Step Facilitation group (median of 26 versus 16 sessions).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several case reports have described positive outcomes associated with integrated CBT interventions in military veterans with co-occurring PTSD and an SUD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/6,16,17\">",
"     6,16,17",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605410633\">",
"    <span class=\"h3\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only randomized trial of an SSRI for co-occurring PTSD and an SUD, alcohol dependence, had negative findings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/18\">",
"     18",
"    </a>",
"    ]. The 12-week trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    to placebo in 94 individuals with these disorders. No significant difference was seen between the sertraline and placebo groups in reduction of PTSD symptoms over the course of the trial; there was a trend toward greater PTSD improvement in the sertraline group.",
"   </p>",
"   <p>",
"    It has been postulated that efficacy of SSRIs in treating individuals with co-morbid PTSD and alcohol dependence may be a function of the severity of the disruption in the serotonin system. In a post-hoc cluster analysis of the previous trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/18\">",
"     18",
"    </a>",
"    ], individuals with less severe alcohol dependence and early onset PTSD demonstrated greater improvement in alcohol use severity when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    as compared to placebo. In contrast, individuals with more severe symptoms of alcohol dependence and late onset PTSD had poorer drinking outcomes in response to sertraline compared with placebo. Randomized trials are needed to test the efficacy of SSRIs in patients with less severe alcohol dependence and early onset PTSD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372926\">",
"    <span class=\"h3\">",
"     Treatments for noncomorbid PTSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs and SNRIs have been found to be efficacious in noncomorbid PTSD. Other medications that may have efficacy in noncomorbid PTSD include atypical antipsychotics, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    for sleep disruption or nightmares. Pharmacotherapy for PTSD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychotherapies that have been found to be efficacious in noncomorbid PTSD include cognitive-behavioral therapy that includes exposure therapy and eye movement desensitization and reprocessing therapy. Psychotherapy for PTSD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31122078\">",
"    <span class=\"h2\">",
"     Generalized anxiety disorder",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20796334\">",
"    <span class=\"h3\">",
"     Integrated CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials of integrated interventions targeting both generalized anxiety disorder (GAD) and",
"    <span class=\"nowrap\">",
"     SUDs.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442816\">",
"    <span class=\"h3\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs/SNRIs",
"    have not been tested for co-occurring GAD and an SUD. In randomized trials of patients with co-occurring GAD and SUDs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    , a serotonin1A partial agonist with low abuse potential, has shown mixed results for reducing anxiety and substance use compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 12-week trial randomly assigned 61 patients with anxiety and alcohol dependence to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      or placebo; both groups additionally received weekly relapse prevention psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/19\">",
"       19",
"      </a>",
"      ]. Buspirone treatment resulted in reduced anxiety, a slower return to heavy alcohol consumption, and fewer drinking days during the follow-up period compared to the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a trial of 51 patients with co-occurring GAD and alcohol abuse or dependence randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      or placebo, patients treated with buspirone experienced greater reductions in anxiety and in the number of days desiring alcohol compared to placebo, but no difference in alcohol consumption [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A trial of 65 male veterans with DSM III-R diagnosis of GAD or other nonpanic forms of anxiety disorders and alcohol dependence were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      (45 to 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/21\">",
"       21",
"      </a>",
"      ]. No differences between the buspirone and placebo groups were seen in reductions in anxiety or in alcohol use over six months of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 12-week, randomized trial in 36 subjects receiving methadone-maintenance treatment for clinically significant anxiety (Hamilton Anxiety Scale score of 18 or higher) compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/22\">",
"       22",
"      </a>",
"      ]. Buspirone treatment did not significantly reduce anxiety symptoms or substance use compared to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373016\">",
"    <span class=\"h3\">",
"     Treatments for noncomorbid GAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatments for non-comorbid GAD include CBT, SSRIs, or SNRIs. Other effective treatments include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    , benzodiazepines, tricyclic antidepressants, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link\">",
"     \"Psychotherapy for generalized anxiety disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31122085\">",
"    <span class=\"h2\">",
"     Social anxiety disorder",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20796347\">",
"    <span class=\"h3\">",
"     Integrated CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial did not find an integrated CBT intervention to be effective in patients with co-occurring social anxiety disorder (SAD) and an SUD. The trial randomly assigned 93 patients with SAD and alcohol dependence to receive individual CBT for alcohol dependence only, or an individual, integrative CBT addressing both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/23\">",
"     23",
"    </a>",
"    ]. Counter to the hypothesis, the group receiving integrative psychotherapy for both alcohol and social anxiety disorders had worse outcomes on three of the four alcohol use indices, and no differences were seen between groups on measures of social anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20233445\">",
"    <span class=\"h3\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;One small trial found an SSRI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , to reduce symptoms of SAD when co-occurring with an SUD. The trial randomly assigned 15 outpatients with co-occurring SAD and alcohol dependence to either paroxetine or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/24\">",
"     24",
"    </a>",
"    ]. After eight weeks, the paroxetine group experienced a greater reduction in SAD symptoms compared to the placebo group. No differences were seen in alcohol use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373228\">",
"    <span class=\"h3\">",
"     Treatments for noncomorbid SAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line, effective treatments for non-comorbid, generalized SAD include SSRIs, SNRIs, or CBT. Findings from clinical trials support the efficacy of monoamine oxidase inhibitors (MAOIs), benzodiazepines, and, to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    . The use of MAOIs for the treatment of comorbid SAD and alcohol use disorders is not recommended since MAOIs and alcohol may lead to hypertensive crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=see_link\">",
"     \"Pharmacotherapy for social anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=see_link\">",
"     \"Psychotherapy for social anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14903822\">",
"     'Drug interactions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14903837\">",
"     'Abuse potential'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31122092\">",
"    <span class=\"h2\">",
"     Panic disorder",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20796360\">",
"    <span class=\"h3\">",
"     Integrated CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials of group CBT added to standard treatment for alcohol dependence are limited and have found mixed results for anxiety and for substance use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      231 patients with co-occurring panic disorder and alcohol dependence, admitted to an inpatient alcoholism treatment program, were randomly assigned to receive either the standard alcoholism treatment program or the standard alcoholism treatment program with the addition of group CBT for panic disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/25\">",
"       25",
"      </a>",
"      ]. The standard alcoholism program was group-oriented and included relaxation training and discussion of how to cope with stress. While both groups experienced improvement, no differences were seen between the CBT and non-CBT groups on most measures of panic disorder symptoms and alcohol use at 3, 6, and 12 months post-treatment.",
"     </li>",
"     <li>",
"      In a nonrandomized, unblinded study, 43 patients with co-occurring panic disorder and alcohol dependence, admitted to an alcoholism treatment partial program, were additionally treated with integrated group CBT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/26\">",
"       26",
"      </a>",
"      ]. The CBT program consisted of three modules&mdash;psychoeducation, cognitive restructuring, and exposure&mdash;and addressed issues at the interface between the comorbid disorders. Outcomes of 31 patients who completed both the alcohol treatment and group CBT were compared to a control group of 17 patients with panic disorder and alcohol dependence who completed the alcoholism treatment program but did not receive group CBT. Patients who received group CBT were less likely to meet criteria for panic disorder at the end of four months of treatment. Alcohol relapse rates did not differ between groups, but patients who received CBT had fewer drinks and fewer drinking binges.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14903564\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical trials have investigated the efficacy of medications for co-occurring panic disorder and SUDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373248\">",
"    <span class=\"h3\">",
"     Treatments for noncomorbid panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatments for non-comorbid panic disorder include SSRIs or CBT. Other effective treatments include SNRIs, tricyclic antidepressants, and benzodiazepines. (See",
"    <a class=\"local\" href=\"#H250491208\">",
"     'Medication issues'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link\">",
"     \"Psychotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31122099\">",
"    <span class=\"h2\">",
"     Obsessive-compulsive disorder",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20796373\">",
"    <span class=\"h3\">",
"     Integrative CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One randomized trial found the combination of CBT for obsessive compulsive disorder (OCD) and behavioral therapy for a co-occurring SUD to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/27\">",
"     27",
"    </a>",
"    ] The trial randomly assigned 60 patients with co-occurring OCD and an SUD to either exposure and response prevention therapy (a type of CBT used for OCD) in conjunction with behavioral therapy for the SUD, behavioral therapy for the SUD only, or behavioral therapy for the SUD combined with progressive muscle relaxation (as a control intervention). The group receiving CBT for OCD and behavioral therapy for the SUD experienced a greater reduction in OCD symptoms, a higher abstinence rate, and greater treatment retention compared to the other two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14903592\">",
"    <span class=\"h3\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized trials of medications for co-occurring OCD and SUDs. A case report of a patient with OCD and alcohol dependence found decreased craving and alcohol consumption to be associated with treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , but the medications&rsquo; impact on OCD symptoms was unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373269\">",
"    <span class=\"h3\">",
"     Treatments for noncomorbid OCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line, effective treatments for noncomorbid OCD include CBT (in particular, exposure and response prevention) and SSRIs. Other effective treatments include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=see_link\">",
"     \"Psychotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4532297\">",
"    <span class=\"h2\">",
"     Substance use disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a co-occurring anxiety disorder and SUD, we suggest first-line treatment with an integrative cognitive behavioral therapy (CBT) that addresses both disorders over other treatments. Pharmacotherapy for one or both disorders can be used if integrative CBT is not available or if patients prefer medication treatment rather than psychotherapy. Pharmacotherapy for SUDs is discussed separately. Toxic interactions between medications used in anxiety disorders and abused substances are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14903822\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20796386\">",
"    <span class=\"h3\">",
"     Integrative CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trials of integrative CBT in patients with co-occurring anxiety disorders and SUDs, described above under individual anxiety disorders, found mixed results for changes in SUD severity. These trials included several anxiety disorders and varied abused substances. (See",
"    <a class=\"local\" href=\"#H31122071\">",
"     'Posttraumatic stress disorder'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H31122078\">",
"     'Generalized anxiety disorder'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H31122085\">",
"     'Social anxiety disorder'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H31122092\">",
"     'Panic disorder'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H31122099\">",
"     'Obsessive-compulsive disorder'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14903731\">",
"    <span class=\"h3\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of common medications for alcohol dependence has not been studied in patients with alcohol dependence and a co-occurring anxiety disorder; however, a study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    in this population found the medications to be safe and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250491208\">",
"    <span class=\"h1\">",
"     MEDICATION ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14903822\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before prescribing a medication for a patient with co-occurring anxiety disorder and substance use disorder (SUD), potential toxic interactions between prescribed medications and alcohol or other drugs of abuse must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/29\">",
"     29",
"    </a>",
"    ]. Detrimental effects may occur when the substance consumed alters the pharmacokinetic properties (ie, interferes with the metabolism) of the medication or pharmacodynamic properties (ie, enhances the effects) of the medication. Clinically important interactions between psychotropic medications and commonly abused substances include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2155716\">",
"    <span class=\"h3\">",
"     Anxiolytics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzodiazepines should be avoided in the treatment of anxiety co-occurring with opioid abuse or dependence, as they have led to serious adverse events in such patients, including respiratory depression and accidental overdose.",
"     </li>",
"     <li>",
"      Benzodiazepines interact significantly with alcohol in that both facilitate inhibition at GABA receptors and result in additive central nervous system depression causing sedation and respiratory depression.",
"     </li>",
"     <li>",
"      Few reports of toxicity between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      and substances of abuse have been reported although alcohol may increase the sedative effects of buspirone. When buspirone is used in a patient with co-occurring anxiety disorder and alcohol use disorder, the dose should be titrated up carefully and the patient&rsquo; response should be monitored. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2155744\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxic interactions between selective serotonin reuptake inhibitors (SSRIs) and",
"      <span class=\"nowrap\">",
"       alcohol/other",
"      </span>",
"      drugs of abuse are relatively low.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8439?source=see_link\">",
"       Isocarboxazid",
"      </a>",
"      , a&nbsp;monoamine oxidase inhibitor (MAOI),&nbsp;should be avoided in patients suspected of stimulant abuse, as amphetamines can increase the risk of hypertensive crisis in patients taking the medication.",
"     </li>",
"     <li>",
"      Potential interactions between MAOIs and opioids include respiratory distress,",
"      <span class=\"nowrap\">",
"       hypo/hypertension,",
"      </span>",
"      convulsions, and tachycardia. MAOIs should be avoided in patients suspected of opioid abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of MAOIs in the treatment of a disorder co-occurring with an alcohol use disorder is not recommended, because MAOIs and alcohol may lead to hypertensive crisis.",
"     </li>",
"     <li>",
"      The use of tricyclic antidepressants (TCAs) is not recommended in patients suspected of alcohol abuse, because fatal interactions between tricyclic antidepressants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      , and alcohol have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TCAs should be avoided in patients suspected of stimulant abuse. Stimulants may increase blood levels of TCAs, increasing the risk of cardiotoxicity.",
"     </li>",
"     <li>",
"      TCAs lower seizure threshold and should be avoided in patients undergoing opioid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alcohol withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2155758\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      taken with alcohol",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opioids may increase the risk for sedation, dizziness and drowsiness. An expanding literature suggests that the GABAergic anticonvulsant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      does not exacerbate the symptoms of alcohol intoxication [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/32\">",
"       32",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       Prazosin",
"      </a>",
"      should be avoided in patients suspected of alcohol abuse as concurrent use of prazosin, an alpha-adrenergic antagonist, and alcohol may increase the risk of hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334568\">",
"    <span class=\"h2\">",
"     Medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions to prescribed medications can arise from medical conditions, including medical conditions related to SUDs. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with alcohol use disorders, a careful monitoring of liver function may be needed for medications that undergo extensive hepatic metabolism (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lower or less frequent doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      are recommended for alcohol dependent patients presenting with severe liver disease. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       Duloxetine",
"      </a>",
"      , an antidepressant, should not be prescribed to alcohol dependent patients presenting with liver disease, as it may exacerbate the condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14903837\">",
"    <span class=\"h2\">",
"     Abuse potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should consider the abuse potential of medications used to treat anxiety disorders co-occurring with SUDs.",
"   </p>",
"   <p>",
"    Benzodiazepines are widely used in the treatment of anxiety disorders, but may be abused and can lead to dependence. Patients with current substance dependence should",
"    <strong>",
"     not",
"    </strong>",
"    be prescribed benzodiazepines, except for detoxification. Use of benzodiazepines in patients who are no longer abusing substances is not absolutely contraindicated. Benzodiazepine use in such cases should be accompanied by increased visit frequency and prescription monitoring.",
"   </p>",
"   <p>",
"    There is an absence of data to support a specific duration of abstinence prior to prescribing a benzodiazepine. No matter how long the period, an increased risk of abuse and dependence is likely among patients with a prior history of dependence. However, a longer abstinence (eg, 12 months) may lessen the risk.",
"   </p>",
"   <p>",
"    Treatment lasting months or more is likely to lead to physiological dependence and consequent withdrawal symptoms if discontinued too quickly.",
"   </p>",
"   <p>",
"    Medications with low abuse potential that are alternatives to benzodiazepines include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serotonergic antidepressants in several anxiety disorders",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       Pregabalin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      in general anxiety disorder (GAD), though buspirone has shown mixed results in clinical trials of GAD with a co-occurring SUD.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      in social anxiety disorder",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      may be effective in alcohol withdrawal, though findings from clinical trials are mixed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trials of these medications in co-occurring anxiety disorders and SUDs, where available, are described above; detailed information on their efficacy and administration in noncomorbid disorders is described separately. (See",
"    <a class=\"local\" href=\"#H373135\">",
"     'Efficacy of treatments for specific disorders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link&amp;anchor=H450954525#H450954525\">",
"     \"Pharmacotherapy for generalized anxiety disorder\", section on 'Buspirone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link&amp;anchor=H72104753#H72104753\">",
"     \"Pharmacotherapy for generalized anxiety disorder\", section on 'Pregabalin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=see_link&amp;anchor=H13590024#H13590024\">",
"     \"Pharmacotherapy for social anxiety disorder\", section on 'Other agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link&amp;anchor=H19#H19\">",
"     \"Ambulatory alcohol detoxification\", section on 'Anticonvulsants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4727695\">",
"    <span class=\"h2\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with active SUDs are at increased risk for medication nonadherence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], potentially limiting treatment outcomes for both the anxiety disorder and SUD. Poor adherence may stem from multiple causes, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor psychosocial functioning, housing, legal issues, impaired judgment, cognitive dysfunction, and disorganization from substance abuse.",
"     </li>",
"     <li>",
"      Individuals in treatment for SUDs may regard pharmacotherapy as an individual failure, not distinguishing between the need to abstain from drugs of abuse and the potential utility of therapeutic medications.",
"     </li>",
"     <li>",
"      Patients may increase their dosage of therapeutic medications in an attempt to self-medicate in response to stress [",
"      <a class=\"abstract\" href=\"UTD.htm?29/18/29993/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should inquire about the patient&rsquo;s previous experience with medication. Illustrative questions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What have you been prescribed and why?",
"     </li>",
"     <li>",
"      Were these medications helpful and, if so, how?",
"     </li>",
"     <li>",
"      Did the medications cause adverse effects?",
"     </li>",
"     <li>",
"      Under what conditions were the medications discontinued?",
"     </li>",
"     <li>",
"      Did you take the medication as prescribed?",
"     </li>",
"     <li>",
"      What concerns do you have about medication?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should provide direct and detailed information regarding the importance of medication adherence in their treatment. Explain that the beneficial effects of medication can emerge gradually, and over what time period, so that patients understand what to expect.",
"   </p>",
"   <p>",
"    Adherence to medications should be carefully monitored at each visit by self-report, collateral report if possible (eg, if a parent or spouse observes patient taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    each day), and biological tests if available. Nonadherence should be addressed with the patient.",
"   </p>",
"   <p>",
"    The patient should be cautioned that he or she should not take a passive stance with regard to treatment because a medication has been prescribed; patients should understand that they will need to be an active participant in psychotherapy in order to develop healthy coping skills.",
"   </p>",
"   <p>",
"    Motivational interviewing has been used to address treatment nonadherence in patients with an SUD, focusing on ambivalent feelings and thoughts that patients may have about prescribed medications and their conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2313?source=see_link\">",
"     \"Motivational interviewing for substance use disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such beliefs may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      He or she should be able to stay sober and handle anxiety symptoms without a medication",
"     </li>",
"     <li>",
"      Taking a medication is a weakness",
"     </li>",
"     <li>",
"      He or she wants to be completely &ldquo;drug free&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4727752\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with a co-occurring anxiety disorder and substance use disorder (SUD), we suggest first-line treatment with an integrative cognitive-behavioral therapy (CBT) that addresses both disorders (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"local\" href=\"#H31122071\">",
"       'Posttraumatic stress disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"local\" href=\"#H31122078\">",
"       'Generalized anxiety disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"local\" href=\"#H31122085\">",
"       'Social anxiety disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"local\" href=\"#H31122092\">",
"       'Panic disorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"local\" href=\"#H31122099\">",
"       'Obsessive-compulsive disorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who prefer medication treatment rather than CBT, or if CBT is unavailable, we suggest first-line treatment of the anxiety disorder with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) over other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such cases, the SUD should be treated as well. Detailed information on treatment of SUDs and on pharmacotherapy of anxiety disorders is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"       \"Pharmacotherapy for posttraumatic stress disorder\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=see_link\">",
"       \"Pharmacotherapy for social anxiety disorder\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"       \"Pharmacotherapy for generalized anxiety disorder\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"       \"Pharmacotherapy for panic disorder\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"       \"Pharmacotherapy for obsessive-compulsive disorder\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"       \"Treatment of opioid abuse and dependence\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"       \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"       \"Pharmacotherapy for alcohol abuse and dependence\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"       \"Psychosocial treatment of alcohol abuse and dependence\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"       \"Brief intervention for unhealthy alcohol and other drug use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"       \"Cocaine abuse and dependence in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest combined treatment with integrative CBT and an SSRI or SNRI rather than CBT or a serotonergic antidepressant along in patients with a co-occurring anxiety disorder and an SUD under the following circumstances (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the patient's anxiety disorder has previously responded to treatment with a serotonergic antidepressant",
"     </li>",
"     <li>",
"      If the anxiety disorder is severe and disabling",
"     </li>",
"     <li>",
"      If the disorders are accompanied by other comorbidities (eg, depression)",
"     </li>",
"     <li>",
"      If the disorders fail to respond adequately to treatment with either modality as monotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H1332692\">",
"     'Approach to treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selection of medications for treatment of co-occurring anxiety and substance-use disorders should take into account the abuse potential of medications prescribed as well as the potential for toxic interactions between the medications and abused substances, and between the medications and medical conditions caused by commonly abused substances. (See",
"      <a class=\"local\" href=\"#H250491208\">",
"       'Medication issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/1\">",
"      Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/2\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/3\">",
"      Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/4\">",
"      Back SE. Toward an improved model of treating co-occurring PTSD and substance use disorders. Am J Psychiatry 2010; 167:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/5\">",
"      Gao K, Kemp DE, Wang Z, et al. Predictors of non-stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post-hoc analysis of two studies. Psychopharmacol Bull 2010; 43:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/6\">",
"      Back SE, Killeen T, Foa EB, et al. Use of an integrated therapy with prolonged exposure to treat PTSD and comorbid alcohol dependence in an Iraq veteran. Am J Psychiatry 2012; 169:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/7\">",
"      Mills KL, Teesson M, Back SE, et al. Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial. JAMA 2012; 308:690.",
"     </a>",
"    </li>",
"    <li>",
"     Najavits L. Seeking Safety: A Treatment Manual for PTSD and Substance Abuse, Guilford Press, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/9\">",
"      Hien DA, Cohen LR, Miele GM, et al. Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry 2004; 161:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/10\">",
"      Najavits LM, Gallop RJ, Weiss RD. Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial. J Behav Health Serv Res 2006; 33:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/11\">",
"      Zlotnick C, Johnson J, Najavits LM. Randomized controlled pilot study of cognitive-behavioral therapy in a sample of incarcerated women with substance use disorder and PTSD. Behav Ther 2009; 40:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/12\">",
"      Hien DA, Wells EA, Jiang H, et al. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol 2009; 77:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/13\">",
"      Brady KT, Dansky BS, Back SE, et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. J Subst Abuse Treat 2001; 21:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/14\">",
"      Triffleman E, Carroll K, Kellogg S. Substance dependence posttraumatic stress disorder therapy. An integrated cognitive-behavioral approach. J Subst Abuse Treat 1999; 17:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/15\">",
"      Triffleman E. Gender differences in a controlled pilot study of psychosocial treatments in substance dependent patients with post-traumatic stress disorder: Design considerations and outcomes. Alcohol Treat Q 2000; 18:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/16\">",
"      Tuerk PW, Yoder M, Grubaugh A, et al. Prolonged exposure therapy for combat-related posttraumatic stress disorder: an examination of treatment effectiveness for veterans of the wars in Afghanistan and Iraq. J Anxiety Disord 2011; 25:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/17\">",
"      Killeen T, Back SE, Brady KT. The use of exposure-based treatments among individuals with PTSD and co-occurring substance use disorders: Clinical considerations. J Dual Diagn 2011; 7:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/18\">",
"      Brady KT, Sonne S, Anton RF, et al. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 2005; 29:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/19\">",
"      Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 1994; 51:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/20\">",
"      Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/21\">",
"      Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/22\">",
"      McRae AL, Sonne SC, Brady KT, et al. A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am J Addict 2004; 13:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/23\">",
"      Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments. Alcohol Clin Exp Res 2001; 25:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/24\">",
"      Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001; 14:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/25\">",
"      Bowen RC, D'Arcy C, Keegan D, Senthilselvan A. A controlled trial of cognitive behavioral treatment of panic in alcoholic inpatients with comorbid panic disorder. Addict Behav 2000; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/26\">",
"      Kushner MG, Sletten S, Thuras P, et al. Cognitive behavioral treatment of comorbid anxiety disorder in alcoholism treatment patients: Presentation of a prototype program and future directions. Journal of Mental Health 2006; 15:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/27\">",
"      Fals-Stewart W, Schafer J. The treatment of substance abusers diagnosed with obsessive-compulsive disorder: an outcome study. J Subst Abuse Treat 1992; 9:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/28\">",
"      Chatterjee CR, Ringold AL. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. J Clin Psychiatry 1999; 60:617.",
"     </a>",
"    </li>",
"    <li>",
"     Haass-Koffler CL, McCance-Katz EF. Medication interactions. In: Substance Abuse: A comprehensive textbook, Ruis P, Strain E.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, PA 2011. p.730.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/30\">",
"      Lehmann KA. Opioids: overview on action, interaction and toxicity. Support Care Cancer 1997; 5:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/31\">",
"      Koski A, Ojanper&auml; I, Vuori E. Interaction of alcohol and drugs in fatal poisonings. Hum Exp Toxicol 2003; 22:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/32\">",
"      Martinotti G, Di Nicola M, Tedeschi D, et al. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008; 25:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/33\">",
"      Kawano Y, Abe H, Kojima S, et al. Interaction of alcohol and an alpha1-blocker on ambulatory blood pressure in patients with essential hypertension. Am J Hypertens 2000; 13:307.",
"     </a>",
"    </li>",
"    <li>",
"     Dennison SJ. Substance use disorders in individuals with co-occurring psychiatric disorders. In: Substance Abuse: A comprehensive textbook, Ruis P, Strain E.  (Eds), ippincott, Williams &amp; Wilkin, Philadelphia, PA 2011. p.721.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/35\">",
"      Herbeck DM, Fitek DJ, Svikis DS, et al. Treatment compliance in patients with comorbid psychiatric and substance use disorders. Am J Addict 2005; 14:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/36\">",
"      Pettinati HM. Improving medication adherence in alcohol dependence. J Clin Psychiatry 2006; 67 [suppl 14]:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/18/29993/abstract/37\">",
"      Brady KT, Verduin ML. Pharmacotherapy of comorbid mood, anxiety, and substance use disorders. Subst Use Misuse 2005; 40:2021.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14344 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29993=[""].join("\n");
var outline_f29_18_29993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4727752\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553244\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31122064\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1332692\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4192449\">",
"      Treatment initiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1332646\">",
"      INTEGRATED COGNITIVE BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H373135\">",
"      EFFICACY OF TREATMENTS FOR SPECIFIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31122071\">",
"      Posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H980721\">",
"      - Integrated CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H605410633\">",
"      - Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372926\">",
"      - Treatments for noncomorbid PTSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31122078\">",
"      Generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20796334\">",
"      - Integrated CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H442816\">",
"      - Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H373016\">",
"      - Treatments for noncomorbid GAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31122085\">",
"      Social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20796347\">",
"      - Integrated CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20233445\">",
"      - Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H373228\">",
"      - Treatments for noncomorbid SAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31122092\">",
"      Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20796360\">",
"      - Integrated CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14903564\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H373248\">",
"      - Treatments for noncomorbid panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31122099\">",
"      Obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20796373\">",
"      - Integrative CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14903592\">",
"      - Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H373269\">",
"      - Treatments for noncomorbid OCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4532297\">",
"      Substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20796386\">",
"      - Integrative CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14903731\">",
"      - Medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H250491208\">",
"      MEDICATION ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14903822\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2155716\">",
"      - Anxiolytics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2155744\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2155758\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H334568\">",
"      Medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14903837\">",
"      Abuse potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4727695\">",
"      Adherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4727752\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2313?source=related_link\">",
"      Motivational interviewing for substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=related_link\">",
"      Pharmacotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=related_link\">",
"      Pharmacotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=related_link\">",
"      Psychotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=related_link\">",
"      Psychotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=related_link\">",
"      Psychotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=related_link\">",
"      Psychotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_18_29994="Primary site lesions";
var content_f29_18_29994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71549%7EID%2F81821%7EID%2F65425%7EID%2F79666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71549%7EID%2F81821%7EID%2F65425%7EID%2F79666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Child, marshfield index case",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Primary inoculation site right index finger, 5/27/03. 14 days after prairie dog bites, 11 days after febrile illness, hospital day 5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marshfield Clinic. Copyright &copy; 2005 Marshfield Clinic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Secondary lesions, 5/27/03, adjacent to primary inoculation site on left hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marshfield Clinic. Copyright &copy; 2005 Marshfield Clinic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 174px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Disseminated acral lesions 5/27/03.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marshfield Clinic. Copyright &copy; 2005 Marshfield Clinic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Father, 6/05/03",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3UgG5xnoTnn3qCV83qxKSdilmJ7e1VprhkvJEjbndwM/nSxREFleQuxbLn1P+FZt3ehoo23LiSLIcBs7ecA5FKxKOEj7tz7A1DlIWYgAY5+XvTrZWzI7ffcZx6ego3E1cdA7R3JBJYHkZ7VKD8+QSAfvA1ATvA52njt1pzsqqvJPfjk0bD3ZIzEjqcYqOSYMvygkjGcVGgb5jMc9wvYf/AF6UlmjOSQOwxSd7FKI6B9ykdh0IpLsyLEPKbLZJx6jPSmJ8pPPHpUmB5pPI44FJ9hPcRmJKnkZIyemKYB5s5ZyRHjcBnkEd6fPj5gfTvTI9x3KMYC8UnqUncdLIRGXJyxJPX2qushZV2d8jP6VM3Eag/eOTn05qOI4KrjCplgPejW4dB6SMhIXPXP1wKWIkudx6LwKZuw8Iz1ByCKVV2lRuzuBY+9MLkcyyOwVTgDn39TUrDzE3gthiOBxgf/XpVzGMr1xz+NRiUl3UKBGgG1vzpdbktkysSi5+82W/ACoZJB17KM/XmmLMTtBGNq4OKZNH5qjH8OMY9aNOg0tdRsjuY2wetV1mkZWbbhwSFU8YHQZqVSQ+GHys2AR6ChslkAUDoDg44qfMvYUZaM4O1icZ96rs5yAADzk4P41Ycckj72OATx61WmwmGVQGbrQVHUeCzJtYsTnHB+lMlZ/m24LDp35zUcbPklhtB4GB0Jp7gudxIA6gDjt3pjsROD99iRn5c9aRid6kFgMcn0wKfERsBU+nJ45/+tVe4kxIsaAncOv9T7VFx+hFOrnABOSd2T29qhkyvyMxBPAO7knmpULbgWGd3Udf8ioro4ZBHHnB+Xvj/PNLzKSvoQMWckE4jXGG7k1C4CE7iQSeausQcI6kEfMKzdSi80tGG5Uhl29TjsRSuxwim7FHXrloLfcM7n+RQD3PArH0G1e3uLuJ5CxRwC45zxW5qunm7t0G8qwIIIHQ+tV7GyFpbbCcljuZj1OfWrcvdsZcnv3Fv086GRSSO3Xmuf8Ah1atb/EPSklJKpdIIwT6sK6R9pQknCgYJ6elZmiQhPiR4ckA63aKe2fmFODb90Ksban07RRRXScgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHl9sEW7kyNpZyCRye/Wr9qVWEvvOGbOR+lU9SItTJKowwft71c0sExI5xgAYH9ayTtoby0VxIgZJnZuFXoPf3qe2dmuGA6bfpzQCN7Afxd6fGirKCO/FNEXJI+Ac46kDFRy4jIJG6RhgD/AD0FKrqqPnna5pQPnDuPmPFK4luVnRmOXbIz90dqf92PKnKngjJpJHZpD8oIx6U/Z2BGDk4zSuy2xrkMxXIyARjHtShsrnuw4FRucvnjinSvtMSjuAOO9NWZISNmRcfd7gdTUEDASMCcs5zU8u0RgqnOaroMyAjnCnOe1JaPUpNWJ5GwjMM8dBTYypU4OScdaYwwBuJ2lsDPApiSYkkKAYGMfnSYa9C1IFB3fwqMZJ5PFQxkNj3wCf1pu/Llv4Rzj9KhzhSVJJPP4Uh2LUzgxiToA2c+tRE5XBGD3/ClkBYxRjGe/wDOlkzs46YyPz5oEl3K3k+WGdCNztzx0A/+vToSzxoZOHI6DpUjjdHEvBZhmlkIRX6EdBzTtYd76kLBcEk8/wAIPoB/KmY3NlWBJGMinDD7iwIUDGB+X86ajAK6sc4GAM1NmUhEcv5pCnKHYMjrxUc5zHvUsQeN36VOjKEYHscAj+dRsMoFJIQYzj1o6FR0IkRsNgYzkE59s0pdQVznJOBjuQKV+AAo+bHzY+uP61GyAMq5yoHy+3bNJspMGYKpLdhuY/5+lVUj2hRnd/ET2q0/KkDpnAHtUDYU4XA7DPek9yohOuUQLnAHX/PaqkkyKkhLbmQfN6jFWnLMwVGyo6iq8oBnaMJluOSOMUmC0KqTC4HmRnpgcjkCo5o0MquWweuO2asnAkYKu3oc+tMkhDncx+bn2Gf/AK9Td2KUiAuHB4OD0BNVJoyMmPkn5Tz0qxJ+7ZVBJJzj2pkqkkBGYHu1Du9ikVZVBhbOAOmAKq6RH/xXHhsnn/TUwT16irV2RFaMXOUXJOT1xUXh5Un8WeHZiCv+mRlfzqqT96xlWT5T6LooorsOEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyjxAJ3miCZCLLl+eozWjDOsUYUHLLxgdqS9sw/mMW+ZSSB261YEQ8g4IGQegrO2tzolNNJDAzhVMg2jPQd6tR5O3GA2MVnOu9kUPtKEHr1q82GJUZHODSRm0NhKOznqA3yipd25h6AdqQBQ+1T04pmdqsQRwKLCQM+2YDv0zSFFLLuIJGcZ7U1TuMgJ5z0BxSNLuYAdhjFFkMTaHV+Mccmq4c71jPzMnGfSpdxJKZ69ahI/fIeu0kH3pbFWJywcsc5x0pkRBkl+X5U2rx371UdnSfOSUJ5A9fWrELMwkXnHHb0qbtjcUiJ5GeUqpGDnHtSSIzxSLG2PmHP8AhTsKp54IHJ700fLFEwJByWIIz9KmzYLQmXmPrhwMcjtT0A2EgZBIH1qBeUOSQSTn/CiMNsG3OFIAxzmmlYGyxJjzHYffUenc05x85XkqAAfpVZHWR8BhjcMk1IZf3m1c7c5J+lMkVpMtuAG4Z/D0FMwOBJgd8even5ImVuGwM+tROVL/ALwbt5wCP8/ShMaFYjAJ3Yzux/L+tMfa6q2QSDuJI6cdKarKyouOGbhf5VJt27QOQecUXKQnlgKoPGM/h/jVcbhNK7jauBn5up7/AMqmMhZVVfvL0OeM9zUMb4dVPKD1P+fSkylsTGMAjcPmbA5pGCFkPGehH61IfmXJ6kfjVaeRRIqgnL5JOOtJ6FR1FkCvt2jlTke5xUDBFZjuOcAYHYc9KUhoo3BIOelMOShJHJ45pFBDnYX4B5OPeoHLCQDnk88Z4qZQN/zHAB4PrxTn3FiTwcnAoYymU+bnGB6cfrUczEMSBwvINP6grICB6+1I+BEM9ycDP5VIIrtteEkHPoar7G8tgSQTzn0Bq1IAOR06AVXkLKAGySSM/SkWr9ChNGvlOsrDL9Pf8Ks+GIN/inRsg7Y7qMgA+9RzRI8illJIJIJ7E1o+EoyviXTtxJPnIfTvRDSVxVFeB7jRRRXcecFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw08gy/AIyQSRVJXkEWCw3AAAAdamuMGSQMcDJI7DNNG0DsBjccVk7myViixkDIwVd/qTg55q1bzllUMTuACnP8ASo1O5nJ/AfjT1HEoYAAkNg9+KE+g2rkxlIkJYdRwPpQHHlqw4yAD9az5ZStxGrZ2DjP92rYIVTk/Kvf1NMi1h0B3vIDwdtNZsTBj0PtxVdZwJZkBCliAtPZsFFHPPIPXFRcew9uqcZA6596GbDKSo69Me1NcgnaDngE1FK2GTJyB2pMaYqsodwRnHQN9KitZ+ZS/UDAApruC5YtgnAxUKHLy4/iPFK+pV9LFl5QV3k5LE/pTm+RFLMPlFVVKp8pIKKSDjuakk+eNfmGSOR25pktlqMERA8c8jNNU42qhAAGfpUeQE8tTjaADioS5UFR8qk4yPzoEtx8KqZQzNgLnp1zUsAO8nHXk59Kis14JOcHnrUokALNkZPXHpQUWNyxAYxvYckeh6VEWQh8DIVcD0z601ziLcQdzZJGOB6VCGKyAEZjJPI+lAkgjUqpLEbgDgnt/npToGlwC7YJ56dQP/r0SLkFn5ycY6/h+tC/d+TOM5Of5D+VK2pV7kav+/ZQj+WRwRyAB2pIQssg3JkMcnA64706SQKm0Bgq8e2BUp/dpsQgj+8aVtDRdiVmJRmHJY9zVCVmZ1UngjJx2qxGuF2ICcdS3c+351CY2FyScsW5JPb6USvoONkSNH03kEVXuFBKoMoSOw7Va+4AMc57Dk1WTcFJkIyScE+hpvYa0Gx7lVVcZIHzGhiFYjj5skLn/AD61O5DYA6AevSoLoICpyN/Tn88VLAglQO4OSFQ5xjqf8KjfDJkgED+nQ1N5b7MAYYcfWoZDtR8gbegI7dKk0iroifaZOPvAAjPNMdlIJHIyeaXPQkEqe9QHzMuVAI3YwaTZZBPs34LYHUY71oeFVJ8S6cwJx56cfjWfOcyjd0+7jrWp4VZT4i09cnKzr/Okn7xMvhZ7VRRRXeeYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB53dyoHk25fk4xUUO53Jf5UHykHuaW4P7sIo+83JHpmnooYMEIwR06VjubMil2+eApyG6gfhT0bE0uT0AH6mmKitKrHoVOTUSElAT0kOT7ChbhcCheaLdkhjuOfTFSRhk3jHyAjHPP0p06gvGV4K5JOahVzkKcfMMnFNKwmVjA00sc27AV8/h0q5kbe52nqetRRfKjAU0E8qT1OQam1htXHu+0IQ3GeaiZ1Of4s9s1E0mSAOig5OO5qJTkP2x39fSkxWsSSgG3RtuR356HNQGXbLn+HtUiSBoSvHXNZshKSonfPI696Wm5Udi7GdkGcgtu9KlMuYSWOD04PXFUVcMyg9iWqRXwNucYz70MT1LyviMhT8zdz6VA4EahAzFh3PNRs6YzuIx1570kbmWZVI+XGW/WhMEXkcpH7N39BUgXdsU4JI+bHoarhssIwg9ef1qVnwSTnJxx60r3JuTk75BngDnp+QpryInyMcBeSTUJOxSgIx1J681HngCQbj1z/n0FU2Ui2WxgdDj86UjYu4nJOD0xj0FRxonyjnPU/Spz8+S7EgevrQ0Mr24cyMSNxI5JPTNTqpAyeX7t1/yKCcdfu/lz0pWwYCQW9BnpQuxXMLuySq4wBkkc4/8Ar1GxUEHAx0+tSqoICnAHU4PU0hiO8leRjCqO1OxRC6sCoCnBPPYAetJOm/YpJJHtT8qkgZmJLnAB9R2ock/NwCTyfakO+pVkVgqRjCknLFfSmy7c5Q9AWz+FW2+aPcOhP5mqcqlZE+bOAcnNZtWKGuvCjcDnk8ZwKgky6naRzjn1pZ2Y/KzFRyMDjIqNSUXJAyOpPpUloSQYQbWNVeZHCsME8Z7D60++uYLW0mu7uVI7aJDJI5PCgDmuP/4WV4QViU1y3H0jbn/x2jlb2KcklqzoZm3SNGqkbR1FaXhZvL8Raau1jm4QZz71xDfEfwgGYprkBHYFX9P92rGgfEvwfa69ZXE2u2ywpIrOxR8AA89qmMJXWgnONnqfTtFeb/8AC8fhv/0NVp/36l/+Jo/4Xj8N/wDoarT/AL9S/wDxNegeaekUV5v/AMLx+G//AENVp/36l/8AiaP+F4/Df/oarT/v1L/8TQB6RRXm/wDwvH4b/wDQ1Wn/AH6l/wDiaP8AhePw3/6Gq0/79S//ABNAHpFFeb/8Lx+G/wD0NVp/36l/+Jo/4Xj8N/8AoarT/v1L/wDE0AekUV5v/wALx+G//Q1Wn/fqX/4mj/hePw3/AOhqtP8Av1L/APE0AekUV5v/AMLx+G//AENVp/36l/8AiaP+F4/Df/oarT/v1L/8TQB6RRXm/wDwvH4b/wDQ1Wn/AH6l/wDiaP8AhePw3/6Gq0/79S//ABNAHpFFeb/8Lx+G/wD0NVp/36l/+Jo/4Xj8N/8AoarT/v1L/wDE0AekUV5v/wALx+G//Q1Wn/fqX/4mj/hePw3/AOhqtP8Av1L/APE0AekUV5v/AMLx+G//AENVp/36l/8AiaP+F4/Df/oarT/v1L/8TQB6RRXm/wDwvH4b/wDQ1Wn/AH6l/wDiaP8AhePw3/6Gq0/79S//ABNAHpFFY/hTxNo/izSzqPh2+jvrISGIyorAbhgkcgHuKKAOKlB+1eWCMrk/hmoLwmMAxtiRehH8jVhxJ9quJIychsbj6D/9dUdSdE+RSWGMk+5rB7G8dSxA7SGOJTkMnzH2JqwGHmsuOnA49KzNJfY7hzhgeh9McVozYDLjHPPSiLuhSQMQzSf7oAqFjwCo5U9KfCxZAT3Y01wp3AHBDD86skasgYlQOCc/Sm3DAYIyOBk1VhkYzSiQEfOcA+9FxJmPYD96ocrljlOAcHAJJpsjbTjjBH61FPKQAFwSOT9Kjlky4yMqf0qWLlGQSYZhnII6VnTSs0+e+RxU8riKTng54zWbcSbbtADyTyanoiktzRe4CS8HngCnQOA5ZznNY7XAec5528fWpoHM8i4ICjnHsKXNcm1jWMg3DAGWPPtVi1YKjux+Y8CskyhyApLMSRitCMgFVzjb1780JdQLQYpHk8ux6+lWlyq46yt2Hb6VThcE7mABXoPftViH55FOfvHrmqSJZMh2puJ+goaMZLjG4Ljf0xk0A5cH5dwOAP608IWYFicM20D3pvULj4kyh67W5z6+lTcbl6hRwoGKYFCqMZ2DuP4qeq5wVG1eMc9vamh3YrIQM5x296anB2rkp0+bufWp2AcZUcDjHrSS/KpA59zT0KTIZY94CLIygHr6jNDyHaUQHd0yD0oQMHYkk7uTnsPSmsrRD5QCSfyNJlLzI51JAOe4wxHvzSvKVRQBuycH1xT2HynHP061XwwkkdiNpAwOvPtSZaFIO3C/dz17ZxUE4UYLcD7uMfhUeoaxZ2YWKaXdcNysMal5HHsq8/0rPnk1O+jJVE0y3POWxLOR7AfKv47vpSa6lJ2F1G7gsVRrqeOKPp8x6n0A6k+wrON3qF8rJYQfZ4W/5b3YwT7rH1/76IrQtNHt7SQzBTNcsDm4mYvJ9MnoPYYHtVp4w3Xr6VOxorvc5HxVo9vH4U1y4uXmvLpNPnKvOQQh8s8qo+VfqBn3ryL4MeBdD8U+H7u61i2klmiujErJKyfLsU4wD6k17d40fZ4O19WPzHT58H/tm3Fec/s44/4QzUjzkX7f+i0raMrx0OeutUbn/CnvBoBP2Ocgf9PL/wCNV5PhH4Rz8mnXBx1/0l/8a9CjdSdrdcUpkX7owWo5vMxSR56fg94T+99imUE8f6S/+NKvwe8IFMi2uSw6/wCkNj+degiTD56GpQ4AIxnPOahtvqVojz2L4P8Ag9k+awuPr9pf/Gpn+DngtQv+g3JJ6/6S/wDjXfkKUAXIPpTvl2hd+D2BpuTQkkedr8HvBmSDYXB/7en/AMaX/hTng3A/0Gc59Ll/8a9DAba2Rn+YpY12x5I5/lS5n3KUUeff8Kb8Gg5+wXJHobl/8aif4NeENxK2c4X0+0Pn+delCRlJ2nIPXikLZJ+XBA4PrVXfcmMdWefL8G/BQALWFx/4FP8A40kfwZ8Gu7D7BOAPW6k/xr0ZEZ8FVCg8dakLkOAOMdafMwlFI85X4L+C++n3H/gVJ/jUr/BLwWjYNjPjGf8Aj6k/xr0CSfBGFBHcU8yFl3AFRjGKfMJRuedD4K+CepsbnH/X0/8AjTf+FMeCMFvsFzt7f6U/+NeihC+FOOTgVJLb+RtR8EHuOn0pXbHyo80/4Uz4JAObG5yen+kv/jTR8GfBhHFhcf8AgTJ/jXqNx5CkJEACeoPUUxivlldw46e9Go7I80f4L+C1XnTrlT73T8/rTh8F/BJjU/YLlT3P2qTn9a9FeSSXJkdcDoMVGu4gqDkYp8zHyHnY+C3gxkLCynBHGPtT/wCNNb4MeDQ+0WNx/wCBL/416MoOzB+p9KsxNEqN+7G4jKtu5FF3cTSXQ83PwV8FeUp/s66DEf8AP0/+NYXjf4S+FNH8G61qVpYzJc21rJJETcOwDAcEjNe2LNujG5ckD5cVyPxWc/8ACuvEag5H2KTPHtVEsufsc/8AJIX/AOwlP/6ClFH7HP8AySF/+wlP/wCgpRVmZ0ru7u6KMYY7m/GqiAPI/oDncRyfSrc8giSUD+JiMjnnNMGwFyvTA/lWNrm5ThRDfmNhyy4P4dKesrA+QQSyNgY9O1RGQLcRPxySPfH+RT70hXR0Gd3U+vcVC0CRPnYqn+EccU2TnBz1ximRyFkXb90nPrSZKsT1j9v51pclOwPgue/H9aZOFO3ABPUc9KdLjIxjJ71VkbaoAPeoasyiKbBkAyOBz/n8KrTFgOT07U6R28xz0J45+n/16qTSBky3BAycd6mRSKt9O0e1jhiMdTWVczlpULPyeasajMFT1rnLi6H2hyeQBge1QmPY0UuTvbnjr+NaVtKwhLLxv6n2FcvbTF3EaYLHkfSuhtN3mrDlQMDj0FPYnc17EM3zLkheAcdTV6LLJhRlic1XiHyiONgExjir9sgJAKkds9KfkTsS2yqWXHPPPPWrjN83JK7OSQagDpuKqBgdBmpYV3HPITrzTTsSSRnfySFGOvp2FTptD4zgZwo7n1qCRgGVIwQByTinvIqFTk56YPrTbsBYUEzbmI29AMVKWIIYqCCSRioVk3LgghjwBn0qZSrHr8ox34/z1plihmkYYA5659KeExuIwc9Mdvao93AwSF9Pb0/lSrIoBZlwBycngetAx4Y/3scZ+vNRsecencDOazJNdjuHMej276jIDgvGQIVPvIeP++dx9qhGk3eojdq94Sh62toTHHj0Zh8zfmB7UxoW+1y0iuHt7cSXl2pwYLYbiv8AvH7q/wDAiKiaz1XUE/064Swt25MNs2XI9GkI4+ij8a1bOwtbSMJaxRxxKcbUUKo/AVIRyxHb8hSuWjNs9MtLCOQWkCRIwyzDl3PqzdSfqTUrlQnHPSp5ELLGEyACcmoZUBZecKDk1D3LSI3QqvJz3JqPbg8gH6dakd2Z+mABzUZBPTAANS0Wc14+hL+Eda2nCrZTsR3/ANW1ec/s6vt8G6iMgZvm/wDRcdemeN2z4Q1zcTk6fcdv+mbV5p+znGreD9RLAk/bmAOen7tK0p6RZhiN0emxrKTuBODxVoKFwyYyPUU4YHCscDpUmVwAcZ9BS5WzJXGtucZZQG7Y71JGSTtcf401EeViEUjAzmpUi8sDJBb3ojoJvoJ9xu+KtC0dovNbHzHI5qMQktu3dOtPAbAG4YPYUxXY2SPBwM5789aniiBjbc2WXk/SgMu4hhuyuBj1pFMYXLlt/p7Uw1YSlfKKhACMYppjBVdzZYgHPTFOd4mRSoIcdQTkfWkhyFZiCQeoxQWOUfvDg8DkU9T8rA4B9cd6YCd2CBSyFQqkcN/Ogm12IdwXoCc8Ed6nlfzId8iHzOgPYiqgJyfm61MqFVGec8jJ6U0zXYjEp3E4IPanK7lG3L8o9BQ4kzjbx6VJJcMtqEIA2jGcUJOwr30I7hg0asOWBwfU1EsvHTikMm9t+3G0DpyPxqASFmbjOOTimaRV0SpJ8539PanGYEuIuUP51Abt9xBRT9R0p1vFHlmlcqMfw0hNWJHcrGEUkbuvpU9sVj++MnrnH6VEqJIpcyDA9e9PhnYArGinPtnFJEbkzN8/ynk89K5n4pN/xbnxIvb7HIc45PFdXCY3f5yN5OCe2a5b4quf+Ff+JBgECxlGR/u1aRDLn7HP/JIX/wCwlP8A+gpRR+xz/wAkhf8A7CU//oKUVqYm5dRyTyyBTtdHJogyI5WHPfFTIxFxdMeT5h4qtIxZmRVxyV5/Ouc6L3MySQSyxxIrDG49OtXN/n2CZ4ZRz9RVO8BgImT76nC+/tUwkj5wcF1z/SknYcoj43+ZFJwpyRj2qVnEb/N69KqTBY4w65yGJ/DP+FTykSIcZPYVSehEkMMmxnGMKDuX6VGz5Tt1zxUc7YiDEDrtOfeot2AD0xUt2LYy4Zsk8A9azJJM/ln8Ks3cuF3N0zj86zZGCx5PJK1DY46GRq8pRcnoPQ1zUSS3kxWMZ3HBPpzWnrUpeRYgT83erWkWSxxgR/dUfiTRFaXFKVnYl06wW2HlqgaQ4OTXQWlmECsTuZu9FnD5UTMwBY8nPr7VejicyISMnI47D60nqTqx8AIkPI59uK04h8wxyx9KrRo24E/U7h096uljHCAAcnrxTWgmNAATOQSeMEVIrMHCrljjg+tNJL546dyMEe1PMgjT5QMngHpVKzBIkTHvj17GnqN+1j1+98w4FVYW2qdwB55780y8vrWzjEl7Oka9FXPzOfRR1J+lPcqxo2wzzngcEk8065uILW2MlxLHFbx8szuFH4msWO51PUCU0+0+xQkc3F0nzH/djB/9CI+lWrTRLZJkuLtpL66XJEtwd+w/7K8Kv4CnsLUjbVrm+JGjWbOp/wCXm4BjjPuAfmb8AB70xdDFwxk1Wd75gQxjYbYAf+uY4P8AwItWxJ8smVOVxgevvT0O9PlAA+vSgtIWIIigAYUAAKOnHt2oMjBiAB+f6UiggHC8HnJpgYjOT6k5/nQBJubByev5VAS0gXOTn0449aSIvIT8pwPwzUjONpKqcjpk9P8A69KxaIpJBHwF46cduKjLEsAwypx07e9Pk2qQiABj81MZ/lAYhe/WoZSIXUhwcfKVwKhaVjg4APTp0qYSAkhc4/vZ7+lRrt+82SQT9KRqjD8aKB4L17aOlhPye/7tq8r/AGer37N4Uv0EUkhN6xwq5x+7SvV/HTY8F6/uHWwnxj/rm3/1q8t/Z1cjwlqCgHm9Y5/7ZpWkfhZzVlaSPTPt8smBHaY7fMwBzUkRvCM+Qgb/AHutSLEu4HlJT6jg1bidTjn5lPIpK7M2/Iiiup0THkHjrhhU0V2Mb2SQcHd8uQKkkVcEDo3QYqMRuqFh0PU+30obtoCsyRLq3Ygo4BA6Zxmp0USLhZPlxn05qm1mrqu9EZm746U9LUQTfu3ljYdNjf40rtj0LsUasmFY+bnCjtio5PlLB/vKeRmqDxzxFyt1gjJVXXOT+FQRte+aXZImU9RnGaOYIxNrzNoOz7rDpTt5QfMPvfdB6VmrPdGDH2I5/vIwNEt9KGG+3lDYBzWl1YfKzSWYxvlccHuO1RsytIARWZJqblmIt5D6DGBTRcSBQwhZW68mi41A1nAL+gxxQ2SflPTuO9ZUlzcswJRF4xnOaebmcbCdqgdKV1cfKbDz7FYtjPpVOV5HUl+M9KpPLM2SrD3yOlRF5WX5pOg/OqcuxUYGlBeSQRmNXAz7daqx3U1vI5RhlwQciqPmvE5AO7PQ1YtpZ5GwIFkY+vNK9zSMLDirHD7w2T2PNTbZAwBbAxmqarKGUqMZ61NI90gKM67fvYIBP50tEJ66F2W4aVleUbto24UbQaQFNnVlbviqMRuA67lUqfVsVeMzW8rK0bEYzvUbhQZvTRE8SOAAASPQiua+KBf/AIV74hB6Czl/lXUQXJki+Rs7e4rnPiiyn4c+IV8v5vsMmT74q0Q+po/sc/8AJIX/AOwlP/6ClFH7HP8AySF/+wlP/wCgpRWpzHQLMss0xXCgyEY9aqtKq3LN/Djb9elNkfZczsuAyO2fcUloWLfMpxjII7561zLzNrWGiH5WaRgx3kD2FZxbypEj/h3dPQ9hWugUrKVx941kXQVzOQMMq7hj1BzQ9Sosnb/j1ljJAZAcZ9KWPOwc9Ouai27p3AOYyoFHnjPy5x0NKAO4y6OI2B6dePWq7y7cog46qT3qaU78gZ21Su+XBUHGetNsEyndylo/mGDjdg1n3c4e3DHggflV+8kHkMcc4xXNX85SF0UgfNjrWctS9ipCn2i7+c/J07Ej3rqbCEbMjcijgdPzxWVpFs0EaFsbGOdw/rXSxGKJMsyKMfMWNadLGDd3cktreUbfMO5OoLetZ2uxCTxDoVtKH+zS/aGaNHK7iEGM4Izg1rRzGfHlI7nA6cKPqaytQgnHivw80jhWcXGMc4+QVC3C5pLoOngEmCX6ee//AMVUh0PTG6QyYH/TeT/4qtSJAAFLuDjIG7rTZAm35WYDPXjn6U7stJGM+jaaJGLQy7V7edJ+X3qhfR7JzkW8iqeOZ3wPf71XpLoB2UFmAznbimSSED5wFycDPNUrnXCjfoVU0bT/ADT5kbCMDhfPk/xq54etLW113U/s6L8iQ7WZtzAENkAkkgH0FTWUjBySePXbT9JDPr+q4+YeXB1x6PTRnOCi7HQI6gDICk8dc9fepMkIATlz3PaqhQBNuN0bdQO3vUpLJ8+eR/DmgzaHupJUtyR0ye1PXghicDp14+lRuQU3J8w649eKWIl23Y2nrjIOKY7DyS4OAcng0cBMnr2z3okYjKjJ9x6Cq8jhZEULl3Bwe3T1pCuWCVC5OM9DxUDuBhfvN09uamAURkZIGMcnpUDqU+ZBuI4ApMIPuKxAJkYktgDmoWjEvEiZI5HrT0I5bG0AHPHNNO3ZhQMH8am3U0KrDynwF5fA46kf0pSN6nJOAflHXmpDlpWXadq9z60yRevIGf8APFSaJtnO+PpFTwdrSsMZsZ1B9/LavN/2c13eDb845GoMf/IcdekePo1fwhrQUncLGduBxgRt1rz79mpc+DdRPY6gQfb92laQV0zCu/eVj1NgsiCI8nPQ0xv3SgFF3D+I9T7VYaIx3OQACp470kuZGYMApNGxmn2J1eOVQ0YyuORTZCiZw/GOmP0rPtpPIuWjzjd39a0JogqLIxzuGetG4PR2YxcqACfcmnLKWZlUK5xjcegqqjvOeOE9fWpoGXJCqAtNASRoD8xO5x6U3y1WQMwyPSnlVRiHwG7VD5qiQqzHHahoqOoPIsbHax2+oPeq0mc8PnjPFEpVMk52g1VlmWRm2Kc54oaNYRtsWiVCrg9ev1p2x2fYQSfbk1mNI6nDHI/lUkV4yOrKcHuR2qlE29nfU0WVgDn7qVEZ5AdoG4DoGqk90mSFJOTk0qXLbgcZA/Sm0hqmrF55tyBX2qV646mot0ZY9Qg/WomlWWQFYx82BtzjmkuUkSU/umVQcAE5/WhIcYPqXLWe1SSX7TaGXcpCAHGw+tQW0jJKDESrrznPWq4mYYYcOPU0SNLlW2EMTwSOtD0Hyl9X3OZAcgcc8ZNPtrd55cbgpHPzHAqnBKYj8yEN7+tXoZwzB3PzHrxQ7MylGxLLZuXMbuGwMkr6VNbwjARSQnc1HK37xQrAjpxVi2mEbFPXjFHL2MWyRLRN7MiK2B1HGK5L4nTSD4f+I1BBU2cmc9RxXWK0e1lOQSMcHpXNfEpY4/hp4l8pTuayk3Ejtjii2pEtjS/Y5/5JC/8A2Ep//QUoo/Y5/wCSQv8A9hKf/wBBSitTmJtZm2Su8ZYgvg+4zzWhbSAQlQ3bOapXaBbzGMgu2B261Fb7t4Ry3ylgjd/pXKr3OjlurF8HdvVSATg5H0rNu+WnHAfbz9KtxyYGHwHU4NUrzdubdj72VI705aIIqxUtLoNDyrDC4PHpUu8OnmxsMOuaZCuF3RnGCQwqo0whuCmMIw+YEY/KpTsW9SwgIlZzIxXH3e1QXMgBBzjByDTvM2Zxyvf2qvctuYNjjFPYlLUz7qUbJME/UVy11chr5YlbDAZPtWzqswhhcggZz/WuZtvn1BLlc+a2SBjPHp+VTHcqWiOo02Y26KZAJIQdu9hkr9a6ayWJgrBUGPzrm4HjeMiOJmGORwBn0NbumyCPapQBT0Dc7T/hVMxa6m9HuRR5aKST0PQVj6sW/wCEt8OEsoOLkcDgfIta8QOAec46/wD1qwtXf/irvD5QEDbcYz/uClEFG6N6/bEascZVg3Hfms3U71khkx83pj0qa6mWT5cfIeh9feqFzELhXCElT+WKaOyjGK+I4S71t3v2UyMsQfAUHjg9x3rf0PVvtjyJjIQ8FQcYPYVmXPhIzahJLFKwVmztA6E12Hh3w/HYQAbRkcnPU1MFNSdzsq1oR1RsWEe5V3KOevHel0oBfEergg58uDgD2etG2QR4G0+maoWp2+ItXzk/u7c/L16PWh5058zNojem0A47nOc9qYoLRoAT2FIWcYIz7A0pUooVPvDjkUAkPjUhcJjg9O9DK0efRjwMYpY9wwc4GemRUuASD0Hv60CYyDzGUeaAp6kDn8qbKn72PC7TzyfSnlyrAn7uOuOvaoR877iPbHpVXRNiVWHfA7AelM+bncBgjrQOuCS3p7UjcAEZ47cnrUjSsRuGJPRVPVu+ajRQp4HI45p+/JByw7ke1LII/LwSMe5qWjQZJlVOTk8kVA4BUMT8uMn9KmwhwF6nHb+YoWPeDvHT+dTuUnY5zxuy/wDCF68F6HT7gjj/AKZtXm/7NhA8G6kCP+X9jn0/dx16Z46A/wCEN8QHH/MPuMcf9M2ryv8AZyRW8KagW28XzcH/AK5pWkNmY1tZI9f3fMORzzjPagvujBDgMBjpzTZpIkYbdoPrUnnQ+V8zAtQjPYzdRIiSOVXx83OeMVKzvMqhz+7J4UHrVbUVWaHc7JtxwM/rVmzjRrWGQ5I7mpi9bFvuXV2gADAI4PtSAqQMDDZ6gUwgBN+Ny9KYZmVtuMD24qxJXFnueArjO3gE1VNwgHOMg5/Cnyuqo27dtI6isy5uCo8v+FuaGjenTTJr67DIAm7a3qapeaTNsU4/SopJfnUZPy89KpzXyJuUkFv5020tWdkYWRqZeZiffoOKYhEce87TkkBSeayhq6wRBgw3ZzgdqjXWVmeT5BtPXpQpxNOWVjfEPlxpITln5xjgCpLduhIUgngdjUVlqAlG6CRCDH5ZDDPBrRkmsYtMjt2gaS6PzCVXPy+2K1UU1czd9g1AWy4cI8LEcLgEE1UQysu0u/lE5HHH1qo1w0hPmMS3QDr0qeK6dRjnpxz0qSrcqLEDlXVXRWAzgGku1kG3c5Bx8vPSmbiwDKjDtnFTLHN5Rdl3Acbj2qJLQzJ7e1nuYg27oQoGeST/ADq5ELcWxRhIbkHavpiqJWWNhgEHqMGpYyEfcCc9z701YzknctxwncrS525xjPSrUipvJXkdahEgeJFVmIA5qaJo2AVvmI70ehzPTViCSMNnZlvUnrXN/E3cfhz4icIQv2OTnt0rqPl3DYAfqK5v4pl0+HXiFC2ENnIdo6ZxSsyG7mn+xz/ySF/+wlP/AOgpRR+xz/ySF/8AsJT/APoKUVscw++jlhv5JMsURj+BJqOS8jeWPa21mPpj6f1q5dzxPJLG4IO8kk/X1rKaOMT4GNhkAyK5XdG8XzbmizfvhJxuC4I9RVe8McrRMGyoOagvwyLhHcHqO2PWkhj3W4Ku2ewzxRqx+ZGHO6f92yiq1xsljCkfMCQcfSpLp2SEy8D5sE56jgVQlZluZshVXggdeSKl6FxEBYW6E55Ud+DUM8pA45IHQdKcJD5aJgqV55PaqkzFVIY8+1F9BWuc74puS1sI0OHft1xWV4fE1vIN5YxsMB15Yd+aj8RTSC+jCH+I5Poa0tIV5piWbAAGAB0JHNVBaXJnrodDY3sKuEXOD2wfTFb6SK2DtOe+BWNawRtEC67mC8gjpWrapGbRSCQ/AO0mm7iNszM0W7afqRiub1+5ii8RaHcSOTCnn7mAO1cqAMkV0MUSNhXBY+5NXFj28LjAHTpQkCdkc+2q6UzM5uldzzja39RSya3ppOBcoGxjJBGP0rdYs/y+UWA7hunvSbsMBJG2fXGf60rI1jJmLb6tp2S73aZ6kAN+nFaEWv6WOt2G+oP+FalqwyFVTx6jFXUDb+DgfTNUkTKT6mRH4h0pRzeIB1xhj/SqmjanBd+JNRNmRIHSHGOOBuBOD9QK6VUUsxOWPvzis7UtNivdok8xbiI7op4zteI+oP8AToe4NAky+8g3AFiQv8Pr+HpT4wXUqXCEnB2/rWLb30thIsGubFDkLFeoMRyHsHH8Dfoex7V0CR4XAzjHOO1OwcyIiFXAVmUnPzZNLFKCBuA3HqDTZtwwY0yc1EGQylUY8Dk+lK5VrotMBgEfge9IQe+Nq+9RZIPHAHU0SkKUy/J5H5UCsSEELx0PTHrULKS2ST8vVRgU9mYsCg6e3So1d1zuCljnjrn3oFsGCpA4BPJzUdxHujZA20k/e9Kk3BcszDJOOKSYeYpI5yM8dBSaL6leIb1VyGXHap423oc4J6Eds1GhLqVwQO/v6Upfy5BggKeDntU6osxPHx2+DNewCc2E+een7tq8v/ZtiV/CGolwDi/bAx1/dx16j46JHgrxCAeunzgn/tm1eW/s4jHgzUGB5/tBh7/6uOrh8LManxI9aZQvBT7vYimYUj5hkdM05Fc7yTkdSp71DI4VQAMc9T6UEkN+sT22Nhzn07VDpVsJrR/L3gx5OB060uoHKIsRyxYd6i0q6MUUyqWXcxU4OMj3qVvY2s+XQsB50jwpDj3pk12HZjMzbmGSQKGlVeg4PeqkkmzcG5BHFWiowuSG5SSLGeB/KsuacCZsHI6AU6fy/LJxtbuQaxXchTlzgZJNDfc66UB+qXhtFZScSnpXNNM7zF2YknrSahOZZ2LMWxwM1VSUhto4PfNcs5czOy1ol0/MpwWOa1/DV1a2l/DJfQLcRBwWR+hHoaxEmIZQmea2ra3iuFVl2g49ec04Np3M5yVuU6TxBDpn2h7vQgIkOXaLcAAPQCrOmTGW1LSBVV1Gfl+YD2Nck6vGDuxkcVp6beS/Z9izFdw2kZ7eldVOom2Y8jsjVSSMScD5c8fSpS2GODxnj6VUjIEiYXdjrnoa05HWWVn2Rx8cIo4FU9Qk2tCzBLMdnns7RoNoXsBQFLMdudp5wfWmwXTIOByDn2qdHZ8u55z0qd9DDmYDerDghuhqY7QoO3B96sRuZduIxvXkEDFKImnLSXLt0+UAcU7WM3LUUGIlQibDjmp4fJGc5PuOlRqhWEIF+UnPI61NHGSo3gBc8t6UXMpak0IB5ZMDtk1znxRjU/DbxGzMNws5Ao9eOtdEqfKGBIHv3rmfilv/AOFd+ItzZX7FJj8qaVjJmj+xz/ySF/8AsJT/APoKUUfsc/8AJIX/AOwlP/6ClFaGBJena00jHI3nAPbk1mSSJGRgM+QeQOprQkuYXM7MRs3HtkdapxLuK7x93JPp7VhLQ2g9CQyiS3iZ87iCTmqvnNEqiNsL0Bx+lNhbYQWz5e4/hnNSXBCoBt+8SfTHFRa+pd+hFI6mAiUDGKyFJjaRZGB3DA5zWhOC8caqfnPJ46Vk30YjSQgAFSGRh1BFS9yokkh2gHPKAY+lZuoy7CXLE89KsmcNErtjdIAMVzPi7UltLWUoDkAkA8GkM4/Wb6X+1t6MCg+Vvb8a6bSbxLVUPKgn5s9CPXPqK4aCUvcAy5YMcn1Oa6OxYGMwiUlWbCOw6fWrv0I31Z6fC4eETRPuwoXjoa0LV13BNo+XkjP+c1yeizNEEt3YoBkjA4J7VuxuY2EjI2QRkgds1RFjpYWb5cIQR7VYEjbgoBOOp21QsZg0bMuAg5ye4q1FL+7UDhz8xO3jPvQTYstx8yqykd8d6QyuzplCScggHrxUlu/mYV+CexHB+hqRgBICByvTjFFiloSwuQP9Uc8delWh5jKMqAe9V4ZlkVTGOlXFYnkLjj6VSBu41WIbHoKeMA8jn1qHJ+bPBJyR2p2EALDqepzQA9oY543inRZI3G1lZQQR6EVkPDd6D/x6LLfaYDzbZ3Sw/wC4f4l/2D+B7Vrp0HTJ5+lI0jMCEIz25oWguoy21G2vrdZbOVZYn4DL6+h7gj0PSlCKpOCCx55rHv7B1uzd6VKLe+OPM4zHPjs69/8AeHI9xxVjS9UF1N9luIza3yrueCRskj+8p6MvuPxA6UrGibRpH5lwAT+dCqFGXGP6UoJIOSAvfvUbONpy3OeOelIadyRyNhAOM+lRM4+VSCzY6e1Ip3Y+UkHrTHIRsL83tmgS8xx2hCcgA+vApqHGM5AxjBoAJIHb0p2PkwAORj6fjSLTQwgb84OarRJOwkN2QRngDpip381WUIu5SfmOegp0ih+2SMj2J+tZy1ehaZgeOJC/gvXkz8y6fcbscZHltXl/7OTAeDtSBbA+3Nx/2zSvUvHMWzwRr4ySfsFxk/8AbNq8s/ZyZ18JagVJC/bmDY9PLStYfCzGp8SPVRPzx1HXBpHG7v1FMAC445/pTZrgxgBRlzwF65p2CxWeRftILciME/jUVht+zsxGSckH3zSXf7u3OT+8Y4b6mnooEZRcfKKizubR0QHAixjGe+ahk27DvB3dB3pZeY8huR1FRy58lRknB5IrQ2RSu4SIMqd2D09Kw7yYDTHVYx5pbJfPNbNw+xTkZ3DArEul22U/BJGMZqJ7HXT1sctvLPjJwDTGkzJk/dqHf8zK5wKarEZFcaTubzui3HLiTC5IrUt5wFG5SMc5HesizOGYSAkEelSSOwGwE8ds1d+Uy5bmlPeHYeWBPO01a0edjKARkntWJGWc89fSui0CzEeZpCcAfLirpv3jTRROjt2EabgfY+tXrcgx8jk85rOhjUsDzzWvawtIcIRn1PSuu5yTkixbZchVXPYD1q8o8v8AdugBBzyOfpVaNHV1JJ3egq5lhgsvJ5z1pM5ZskibCAHcFPp/KpUIDEsWPoKEV0T5lO1+eRmpUkG/jGAevr7UkzJ6CAsMMfoAachxuVieew6U9lJn3ZwGPQVKwUOCcNjgketGpN7jtw2gMOF7ZrlPiiyt8OvEIBPFlJx+FdZM8R2OFVQeAAa5j4o+W3w18RnGJPscmAPpR1M2Xv2Of+SQv/2Ep/8A0FKKP2Of+SQv/wBhKf8A9BSitjE5DwXqLahaXUMjLvtbh1POSRuJH4Vuxy+ZLPlO+371eYeC9Uew8Y3MIcNDcyvGVIwM7jivSjIqtuZNu7j2zU14WkEJXVxzN+6VV3Lkjjrg5ouHUo/PzgYxjrSXw8uHtgDIJ7EVDfyjyDJnB28HHtWG2huiNJMRo3+z19Kyb+US+YNzFBzkd6luZH+xpwMDqBVC+ZUSJTjI5IXrj3rNmkSP7RFBGC3BC15543vRNI6AsMnIOOvtXT6vJm2YxZLON2CeleeapMbjUn83cFGQQTnBAoWoMZpUo8tQ64znkc5Paug00uHw+wbgTjHIrlraNDKgB2gndg9Oa6LTJWilMU7Ek8DHNWyVsdvYyzTJGnyvJHhw/QYHf+ldZbi4ZPLZ1dsZG1a4rTbowXEI2dCVII9a7bT3VCoLfiegoRm2Xobdsgy7WHoOP1rRXzFwAx/FQR+dU1kCMV3Jg8rk5+oq3BMwxhEbHbdVBcuQmR8ptjb25B/KpxJIpw0ZyO4IqrvLLvVfoQRTxJK0qDClsHjOKXUaZct2ZXfamCcds1bxIDycd+OaqRvJtxsA7ZzmplEh6n5sfwnimhkhLl9r8E89OoqQsuMMW3DselVmAPX7+OnNOWP5cg5HpmmSSISWOdzD07U93CLhFC+wpiY2kDBA6c04hnUqvX0pXKRFvCuRjqRior6xg1GFYrheUO6ORW2vGf7ykcg0rblKRY3HPL1ICM4JI9s4oUinoZS6jc6Uwh1eQPbscJfqNo+kgH3T/tfdPt0rVU7mVUJ2gcHqAKTCy7lYAo3ykEZHI6Gsb7FdaOzHTFaexHLWRPzIPWIn/wBAPHoR0IPY25GKqETgk8801j/tck9O5NQ2N3balaiW2begbDAqdykdVYHkH2NSsgBy2Qvf2H+NAwUs0W4kDJ6dTinxMTuBXBU9DjBpgYtIAgGB1x1qR+xIBHselTfUEtRHOEOSdpHODzS7lHQcDt3/AM9KawYo2CcYwAeAKjJZEAZ/mzjPT/8AVUsrYxvHDbvBniBdwONPuD/5CavK/wBnKQx+E9Q54N82f+/aV6f45ZV8F68ODmxuOR/1zNeVfs+TxReENQ85iB9tYgLySfLStIfCyJfEj1K4nREzznPWorfJk85x+9H3R6CoVDsyzTLk9VUc4qKe4bztkeS7/dHpRc0SLAdbm94ACxcnPOWxUwdElDNGroRypNQ2arENhwevJHepSwAG1gGA6VRS7EDBeeck/rUEgeHHVcHIyKncjG5u3JNMY+crLuPy8AnuPalctXKLr5kmGAZev41lXUJV5EcYjcda3REp4TIIXp6+1VpIS1vjGSvYjqKbXMjaM7HnOs2X2SYg8g8g1nxu0nCjIHSu71TTVuAMoPoOtZJ0iON/3QZR3zXM6bvodaqqSszDTzQgUnA96ljT5x8xJzg8cVvw6RGx+Y5Ppmr9vpkCMpMJ/Gl7KQnOKM2w08OVkkB29hjrXQQwqAAq4x0q1ZW/zKxQBR04rXijMjgLECB6CuiMVE551bsqWdtkZfoRxWpBbxMygMVAHJ61LbQ7pArxkj0UVYa12zFQCo9+o+tUc058wiwDftLhz6ircSbIyvl/VjzTfLKbeBjuR3q1Ckg+RQcAZoRjJ2ZCFkGNv4VOkLGL7gPPWpIgU+YKMZ796fCwyzHcvOeOmaRDnciMZzschSD360zbs+R3+Y84qRwGfc53ZPPvTjE0jr8pPpxzQ0CZGECkAHODzmub+KEaD4eeIy2c/YZMEfSunnZWflSvbA4xjiua+KQT/hXHiI5O77DJ/KqSFJl/9jn/AJJC/wD2Ep//AEFKKP2Of+SQv/2Ep/8A0FKK1Oc+drx2h1y5ljOCs7FT3HzH8q9t066ivdMt5gFKugbPXtXh+qr5Wp3rE4HnP97p1PYV6H8OdREunNbFt0kLdOnyH/69b4mOlyaT6HX3MhW2aN2Lj7oOKoXzqY4ot4ILAH6Dk1LfkpCQ+dhOcDoO/wDhVFpNw4YlhwAPX1rzm+h0RVxlzIsj+UQFCHOe2f8AIrF1yRMF03AkEdOtaJBEhXaGK53NyM1lXoUPlmJQhiQeQKiSujWKMLVL1E087MBwnLOMc/8A664W5Cpt3ne/JLdct/8ArNbniW5ySued2M9qwYZGjIAG1hyr91NVG9hSYo80SLG6bPlBGRgj8K0LZxuXYCHHIJqK3k86/kkkZ5HbCs7nJJP15q5bDZdZXHpnsfpTaEjrLC532mW3MzDJHUbh0rr9Hn8uNUJPAweCdv19RXHaXEo3rEz7FwxyOldrpcsbRKqYPGDjqD60LuRI2Ij+6JUkEcjNaMe3I3Hj1xxWTDJ5hjUDb03Ee1asMgBKSKFYjPHeqILkboAxIODz+NSBwW3DsMjNQxMqEBTkHjBFP2ryyuEPY9qBluGfzVVlXaR61ZLM2TxkjGKzbdpA7gDHOcjFWirAj5s49KE2GgpLAnd+JqQFsAqxIPrUBJ37WbtmplkVeuQfUnrQO5Ii7c56n+9UqNhflA55PPWoSc4xwfenhhsIY7SBjOc0FDjwP9o85pm04P8AeIyRTw2M5Ix/OguGJ6HPpQO41fl3jv2PvSHfIxPP3cZNMzhcd+wqZG2jofagZk3ull7lruwn+y34GDIoJWQD+GRe49+o7EUWWrb7j7JfxG2vwCRGTlJB3ZG/iH6juK1nUMQCCM1Q1LTre/hEN0hIyCrDggj+JT1BHqKVy/QsDI28nb/EepoD7n6NjJAGOlYpubvSF2amWnshwt5gZjHYSgf+hjj1A61sxvuQMpDKRnIwQR60tSlqSvhWAUHaOpNVbliRtAHI4xwKfI+7JLkk9qhYKmctjsfWpY1uYPi9SfBmvEtwLGfAH/XNq8t/Z+VP+EYv3dckXjAN6fIleqeNgE8Ha70/48Zx/wCQ2ryb4DmVvC18kPX7axORwPkSrjpFkSVpo9MubponVEGZOw9Pc0qxiFFkc5ZuDzgfT6UxLXY5YyOWbrkUk0RMkaupKnJ60J3NNiY3CMx24YDvTVW7kBljRFXOOTg/lVqC0yONq56DoKnjiVVZSTnocdKYrlDYrKDMzbh+VTpCzDKEEYqZosLuUAox6VEqmN8rlQOcUBdjCo5/hYdqrGCWVWIXJHBFaMqhsMADjrg5z70yaJSN0btz1GKoE3cxdro7YUHPHzCgxFiN0I9hjGaviJw4GQMngmpYo2JG9mz7Gi5tz2MlIELbggDdwa0YomYZwEU9gKux2tvuiB3E5+djVlLdFfCvxmnciVW6K0cQKgbCSBwauRpJGAyIcYxkCplQgliScd8VPLOXVFKj5OwGKRi5O5AscxQPsKqDjd71Y8p8FyQQOD9aaSGbEZYjqQ1IwdwcDBHf1oaE5WJ/KZohkfIOhz3qVS6rgE5PGRUaExRKivuDdRnpTlRihYEhR1oRN7lksTGNykqOTSxhZW2KcfWoouYwN+FPUk9qmeM5AjOQB1Hen1J7iDZwFP3eeaUyvlsN7+n5U2K1Mku1ZVHqSeBUEqsHODk9jSkOI3ZPNI2CCijccnkk1zfxPZj8O/EILYH2KTgj2rqIomcSSAqMD1rl/ikrJ8Pde84EFrGQgY6/L1pq6Kbuav7HP/JIX/7CU/8A6ClFH7HP/JIX/wCwlP8A+gpRWpynzhfqW1K+ZWJHnPnJ2/xHvWl4TvG0/WIHzhHbY3oc/wAzWTeTM2oXysRlZ35HPO49zSRviTcrAOpz15z9a75x5o2OaLaZ7TNKksOBl2I4H+NZluCl3JDt24AYketVdG1Bbizt7h2BZxh+Op6fzpLyULevJESAV2nHGT1z+FeNKLTPQi7q5PeStFMrALgZBH+Nc5qN0DM6k7SRgL0zWvc3K+WQs2ehznPvzXF67eDzZCrZccBv61Oha2MDU5Xubxoxyi8kfTmo0hzM8i4Y7d3X5c+lU2nJmACkljnr79TV3PlLAq8ELu4/i5qyXqTwkRpEeqzHd9CO351YtpNsjLICS3A9j6iq6EMwABC7Syj0zUsSshByGRj8w6YPvSA7KwdojFgjJ5bI68da6OxWIruXqOc+h7iuP0qJ3gU7jjtz0rrLQiJFC9Dhh7/SqWpDN6zK7AD8pDcdvyrVV/kUN1HesVSGUbCDxlTWjESQofB9COtJok00G6Pg8dwD0NPQFSCDlfRuazPLcHeGOD1GeRVuJHKj945Q0wLkQVpXIGOAAQatBcgktuOMVSzgBVKrj2qaMEcgnB9TQBMyqRggE+6inqigZHTrjHBqLkZ3Hj9TT17FScH160AWFIKkAjA6A0btvTJI689aiXCDGcfrTiwMfQAY64xmg0JVQAlyxK9MelS/KMHqDUJk2k4x8w5z6007iqnt9aAROo+bI4I6USO3AQHj24pN/wC7FKXIXODkdOlBdiRGYHC89+eKNobO7Ge4pjMwwRgewGc04nAUq2PXrSGgdV2bW+bt0zXOzWM+llptHG+3zl7EnC894z/Cf9n7p9utb0rspLbcDtVdp+CMc96C46lGy1CC+h8y3Zt8ZwysCrxN6MDyD/kVMPm/jbk+p5rO1Owjnk+0QSG3vVGFmXuP7rD+Jfbt2wags9UInW01CMW94eF2nMcvujHr/unke/WkkapdxfG7IfB+vDLHFhPg/wDbNq8u/Z8Xd4Uv/wDr9bn/ALZpXo/jKc/8IhriEnBsJx/5DavOP2fJhH4Uvx5TPm9bkD/pmlWrOJz1L86PUkVNzK65bHBzwPemxL87jgjp06ULKASxglA9gKSKZghZYWIZt3PFTcEyyQqrzkA8cUq4UMQVI9D1+tVvMkk6xKB7twKcWmDMAYio4780ykx4O5NoLBhzjtT8MUDL9eBmqu+WNwyyBT6hOKSOSZGdfNkG8YIUdaBgWeK42jPIyAaZcSFeUzj09KimEiusqvOuwjkCp1EUmSxkz/tHvSv2DYIk89AxPPYVa2qzqdwzjoeMUkcFrIMIxXHOCxoW2hEnyHcAetUIliaNXxKoYHtmrP7ssCHUbu+eB9ajNojp5ik5H3uPyp8drG0fysAw6Ke9G5N0TuoibYk0cq4zmM5FOV0biRc++KhCn7rYGBwBxU0CSMpYZwO4GaBN2FZwZsg9Bzgdqm3naVQHB7Y/SmSMpQ7QwYHknqajBYkYYjkUEt3LULYU74zk8Z9KCoGAVOD6U2JnU8dDkc1Oh24YAnB6dRTsCaEjRWXnPPQVLG7uFWJiOcYzyKjeOJ2DByMn5j/dpgg/eKVfac8MD1p3sJ6kkm8ITgZBwTmoJdyxqxcZ+vT2pZIWD7xIwx94A8UiRpPKFOVTPU96lu5UVoREOkYY/dJ5K1znxPd5Ph54gD5+Wykxk9sV2M0Hmr5byDanOK5P4nKV+HPiIKcqLKTIP0ppO4NKxp/sc/8AJIX/AOwlP/6ClFH7HP8AySF/+wlP/wCgpRWxzHzHqqRxa9elmI8y4bCjpncec1I2wfKpJOOuf6CneJVEl/eAJuZJnYAD3PpVG2kLRAgbcgAj/wDVXpWOWx2fhG7UM1vMc5YOp/nXSXEaEkgZ9c155Z3IikhkTnYw68V3NxKPJEyyHDDIwa83FQ5ZXO2jK6M3UnWJyF+UA7R7VyOpsm9QmS798fWt2/uB5W9wN3OB7965qWXfcljyAu1ccAE/5NciVzduyMtvm3kcFicH2FaLsDBG5QEgOM1mSZE0Jj4KknHY881qIzeQy7QecjPQZ4zVMzQinvuwFwBx1FaNrCJoCwJ3D9azo1zJsYjdy3X0PFX7SXDuVIXa2ce1NCbN7TSYWxnKMBkdK6iymD4RuVVRnHpXOW2RCWQ5I+b657Vr2MoX5QPp9KYm7nTW+DGoHGK0YZdqgZ564rFtpQYwucMvf0q7CTjGQSPTtQI10fIGBkHp7VMpIBCk5Pp2rOtrncxU/e68VdWUADLcAYJpIaLcbEKGK5bofYVci5HvjtWb5wOQpBA4qzBKXAwenAoBouqozhvmA/SnbQF4Y4HbNVlnKSZPK/zqYMNoxnB5JpgLneQACB7092+7jtxjFRF03Fcgn3pxxjBJOD0oKTJFcbj1NT70dfXPtVeMhAM4IHOc9aIpTk4x9fWgaJ+nJY46fSnA8D5/l9cZzTRJkAKuMng4pCrD7v4jPBpGiLEYJ+917DIp7LwHx17GqyzZB4GBxmhpT1D4zwM8UAkJcyFQAQCvXFUXwpLDjHJA7U+6nx0PWsK+vt0oiTOScL9aZ0Uqd0Wp5AZMs2CBz6VTmiW7iEVwglhcZw3Y54II5B96y9Sv4I4UZZd7EZOG6YP8qs6XeCQhQeSO3pWaavozq5Eo3KPimS8svC2sQTh722kspkSYDMkZKNgOP4h/tDn19a8V+H3j648H6RcWK6K14JpjNvMhTGVUYxtP92vpOHnoOc88cVbjcqTkH5SOfWtFJI4qtK7umeCt8ZLxgR/wjbc8f8fDf/EVYT42XipsHhjPpm4Y/wDsle9q2cHgH19K1fDiga3Zcf8ALVf5004voYODS3PmxvjNftjPhc4HYTN/8RSn4zXxXB8Ltn189v8A4ivuaitORGKqSR8Lf8LjvyMN4acgdP37cf8AjlPX4zXqjjwu+71+0N/8RX3NRRyIPaS7nwu/xlv2jKf8Iy/P/Tdv/iKcnxnv1UD/AIRdjj/pu3/xFfc1FHKg9pLufDf/AAui93bj4VJP/Xdv/iKD8Z7s53eEhnOcidgf/QK+5KKOVC52fDQ+M98AdvhiQHt/pLcf+OU8fGzUAoA8MyfjcMf/AGnX3FRRyoOdnw+3xv1JmDHww2R0/ft/8RVm0+PerWwkEfhlwJAVYfaGwR/3xX2vRT5UHOz4lX466iOP+EUO3I489v8A4inS/HW9diR4RKL2AuW4/wDHK+2KKXKg5mfEo+OuogYPhZiPQ3Df/EU9fjxqAYH/AIRNseguW/8AiK+16KdkK7Pij/he9/njwm3v/pLf/G6X/hfOo4I/4RQnP/Tw3/xFfa1FLlQ+ZnxOfjvqJTY3hQlPT7Q3/wARSj4734/5lI/hct/8RX2vRT5UHOz4rPx6vz08JMB6faW/+N1m+JvjLea74d1HSm8LNALyBofNFwx2ZGM42c19zUUWDmZ4f+x5G8fwjdZEZG/tKbhhj+FKK9wopkn596gxkvr5Cf8Alu+QOeNx5rLhMwndWUGIt8rHnP1FXLpw2p3vBI86TGef4jVS7VY51nIZUA2k9RXpvXU5rs0IXAK+YuSecD0+grZtr0tZJGzYSM4+vpXPQP5jZBLHjBJ4rVhA428CQYOeeR0xXPiIc8S6MuWRBrFzuV3A+UfKo96ysl4SvWWMHCjv6/jU2oTKkhjXkxjkn19qzELFCwJ3EZODzXlJHdLUiRlEoL4wBxn37Vqx5EchAYkoAfbPSsaZ1MyI0ZJLdR1/+vWqJcW2WPOFUY6A4pyRKYyMqkh+UllHBzVqF18/Kk7icZ9c1SjZlMrEAv0B/p70WcqZdTuBX7hP8qcZJ6Ckjr7OYowwQV7gjjNattIUkG09R0PauVsbg8HcMCt63uBheMgd6qxJ0UE2B24/lWnb3I3ZfAPbPesC1l3Lz97p1q9AwIG6kM3WcbVccY6j2q9DNlRkYasBJmX5X5TvgVchmUYIbjOetA0jaRlzkE7hU1vMNvOQ2cisxJvmwhyf61chOAOuAKRRpCUEcHn1FPWVl4woHXNVFdQODnFTRMDxnn0NBBZWQAZUDPvUkL/OQx+gPSqwBViUIGOoxTxvDLjH1plPYub/AJv/AK1OEnzY69x/+uoFJQAZz+HWnb8OMKSaAWxZVtww5Cjt/hTkc8kjJHIxVcksuccdcU5WDEd++M8UWNEiZhnk5GeCMdagd1jyDgYHvSs2R8w2r0OKrznA55Y9/SixcSjfys6DbkA5PHFcnrrTLG7woTKpDKR1yP6110qFz904IxntWZc2Ikf5sjGe1JnZSqKOhwjRXd0Glk34lzgHgZ9K6zw5ZSKivIACFAwvHSr0ekhZQ8nzsvALknH0Fa1vbBUwmRn9azjT5dS5VdOVDoQwxwffNXG+ZMZzkd6gAGe2Ac5FTxfdO1vy7e1VYwbBDsYgLxn8K3PDfOs2Rbr5i9/esCFmUtvXnODxwK2vDTZ1yyw3/LVePxpxMJbM9YooorpOEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD879WHk69fndvVpnPIAPU/pUrgTW235cAZJcZz9c9qb4kXOq3ksYwyzPyv+9+VQWjKeqj5uhPNekcl7jLaRCXXhCpx7fh7VrQu37sv0UcZ4rJmCJfK+4AEAbcYB+lWkZs5wMDjrzRbSwX6kOqqi3D7iSGw+4HH1rOluFCERjA5H1FbWrQl7EEn54/mGB2Nc47Bsk49xXl1KfLNo7Yz5loMCk3cbowOwhsH/PNTTylY1fACtkkn8M1TV1kLE8EnipxuaIxthgw6Z680SgJSL0EhuMhOnGKSZQY/l6qcgiqdtMIpTHzsZvk9RWnkTEiRgsn97sfr/jXJNOErm8bSQafckMwbhs9K6Cwu+NpPI9q5SWJ4n3rkEfka0rG5VwpGenrW0ZKSM5KzOxgnIO5ehHI9a14LhmUEcjrmuRtbplZQPu9xWrbTA4wx9xTEdNC2AAfwq3EoPzEDHp6VixXBC/e3Air0cxK5U/hSHc3ITtAxj8KuxzbeoOT71hxSkYweR1FX4ZNxGSeen0oC5sRyALkDjHXFSxOGJKgY9u1Z8LHJwxKeg7VPHhSDyDjv3pBY0IyydcdeoqZWHGzoTz3/Cs+OXAPAFTow3KQAp789aYal4nbyCc07djkkAjn3qr9oAOGO0dz2p+0uflfd3IoDzLKvn7rcDg+9OilTaDjKjjPTFVoyV+/jHAzRMpMeUO3ngUFpllyrMMEk9j/APWqJyC2MZyOo60yEFTg5bHXNSMMfdzgfrTRVyEkchyM9h3pkQDscLn61MUUjdkkfyoCHhiMg1JopEbDnKgGnk7hjp7E4oOQCBgUsAxy35n+dNlcw2C2jjOcMVYg5bmrW4Jgquew9KFA3MwwSRxz0oMwOSTwoxgGpsDdxJGHfr3H9K0/DQJ1+xPbzVIwPesssDhuOn41q+F2B1yxA6eavTtzQlqiZbM9booorpOIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD88r7dcX18G3A+fIM+nzGqNhI4+RyCQSKuahtTX7+MYw8zkD3yazpdsN30b5zjGTgV6XQ5LGhdw+ZAxIBK8jHT86S1nzGvlnGRySP1oViw+fIHpmooS0bkbiSWztY5Ip21BLSxrRKZIPLb7pyDgA4B71yU6NbvJC4IbcVPHOPWunjuO5wD3rC8SREXfmKWEcyDntuHauWvC+prSlpYy42WM427m6fSpCwE6qpyq8ZP61EG2EnAye/pQX252gHPFRbQZZeMSYYYyOntV0nKK3Ru/tVW1bOMYq6VHGRjP86xxlP3FNG2Hl71hgYkYzxUJ3QuXQ8dSBUmCCcjkdaDz17150JcrudbXMaljdCTB/Eitu3kUkbcj1rjUkNvJlc4P6Vv6bdbzgnkjOa64y5ldHO1Z2OltpdrDBPpntWnbzKfl6EfnWFavgnOBnkelaMDA45yKLCNtJQ/IJOe9X4HA5x7gisGJuM54NaMEu1eDz3FIDZhkYgNE2CcnkVZZ3KfMcNnPTvWTbSbj8ox39KvLICCDkk9eaB3NSJjgc59exqwrDGGIGBis6OTg7Tgdamifo/qKAuXAdxOPzzUsEqqvJ+aqokG09SQOKEf7pB4xg0D6F6NxIDtIPHY5pySF2GRj19TUEIU8qR+PFWlccDjrVIV0TPMFI64pwl35wMelVHYjJADEfpTklyoGSD6ZpqyKRM645UgGm5wDtwR6g4xTMthj96jcVGSMA9sUFdCYZBwME98ih22jJQZB7HkU0Z6g8daa5ySWz9D3qWjRK5I7hQvOR0AH86RE3MSx/KkRXIyOq54qZVypIXjjtSasVcSMZycjbnn2rT8MIB4gscjH71cYPv3rOdAuDnHfitLw2d3iCwJH/LReR35pJailseu0UUV0HEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+dOunZrNzIQcLcvyfTcahvg5GVCkjnI7jvV3XV3anfAHarTOCMdfmNZsQLW5iY8r8p+navRucpd0+cFThcn3PAqK4UJdpuB3sMDauBVe1YpKUxx0zmrl2rvFuiySDjJ6Ad8mmLqWIQEOQBj26fpVbVoRcWPGMx/P8A0NEbkt8pU44HOfyq6qjy1RuVb5SPwqZrmRSepyJA2pj0xn8aYy5TI6CrN1F5Uwi/u5z+ZqNejKTwBxWCRd+o+zYAVpA74yD9ax4CQ+K17Y/Lj1pySnTcQi+Wdxme9B5xzTTkNgUV4b0PTWqFZd3WnwE25BJ+TPB9KYvSlznjtVwnysmUbnTWF2HCqXGR/D/UVsW8gCYOTn9K4S2uGt3UNkr611Gn3W8L82a6U77GDTR0ULDAxjb6GryMCvH3wO9ZEL5KjHWtKDlSGBzQIv202QMg5HTNaKSbgOQPasiBSoYAgj9RVyMtjAHPWgDRjlycHOetXLdyUXpj6VmKVK9cbeasW82RgHoefelYDWB3DqAfWkO5G4wB25qvG+VPFTA/IS2TnjmmUmWVZiM9cjlcfrUoO0c8nFVIZMLgjIHvU3mgoR0NIdi2HGBkfMPSpEw3PH+FVl5UDHB/CpSwiQljkDnOabVtSUTooJO1jkcipBgjjk46iq8fzncMZPQCnCYBtrEbs4p3SLTHEEZAK7hyAaljT5QTy2OajA3erduaXkKcMF+nNO5aZYAUA449hSvLsHIwv61AWZVDKAT79qOW98VL3BDyDJyW49K1fDJH9u2HPHmr+HNZK/IR8xGe3rWp4XO3X7EADBlX+dCE27Hr9FFFbHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+eusqTqN6FP/LZ8D/gRrIZdjISD83yn09q2tZP/E0uh1/fvz/wI1k3aiUkLgADr716XQ5SKdTFKrKoJPUjpj1xVyGQtCykjGOeKon99aBwcOOvfkVPZTB4hwB65NJAxbP92GAVgBwN3f3rSjYtg9PQ9qy5d0NxuHKuOFOeKvW0q43ABR3xxTQIztfgxPHP2YYbjHIrMA/eDNdHeRm7tJVAyQNy89SK5xztwQKytqVe5ETibj1rRtmxj0qhNjzAQKt2zEnBP4Uo7jZYuMLJx0NRg1PdL8qN+FVh1rxq8OSbR6NJ3iiQZ70UZpKxNBwCsMNnBq1Y3JtztY5APX0qqPWlxkdetaQm4kSjc7CwvA2zJwK37eYFBgncO4Nea2129uy5yUB/Kuu0rUVkQZIP0rpTUtUYWsdRC53HPJPNXlYMuQMnrmsa3lG49weMZrTt5QwwenSgC9ExYZxx14p0RwzhSBnvUMZxJuUn3q2iIeSOv4UCJ4JCwCk9O4q4MsVXJ56iqkQA45wKmB+XI4PtTsMsrg9gOPxqXG5GC/eHpVcNjqwqdCNxwcZoaQFiCUpGGAJHTnnBqygV056Y5rMgb94+BxnAq+pOOe3emthE8ZAIC5qMg+cGB46HNAwBls/XvTmG4DHbv60mik+hMnXHIpybSSc49feoow3JY9ecDtUis2SBzkd6IlEowBgDIpxwwG3HPfpioVb5ugIH60buepAP6UOw0x4BIJ4+ua1vDPOv2P8A11Xj8azAuFzmr/hZy2v2Ix/y2XPp1pLcG9D2KiiitjnCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+CNTgj/tO6+XrO/c/3jWVLbRbm+T9TRRXoo5GV7S2iMtwCvHB6mpLW1hDyHZ/F6miioW6KHX8Ef2UnbyAMcn1qWztYXjZmTJyOcmiiqQF+GCP5fl7+prm722h8+T5P4j3PrRRUTHDYry20OPufqamtreLb939TRRULco0JbeI24yv6mqwt4v7v6miivPxX8RnZh/gD7PF/d/U05baLH3P1NFFcpuOW3ix939TQLeLcPl/U0UUhCyW0OSNnH1NT6ZEiXQCggfU0UVrSM5nY6cikZOc/Wt4RIrDAxwD1oorcyNG3hTP3evvVgRqpTA9e9FFAFmBFJyRzU7RpuXjrRRVAPaNckY6c9aUopYgjg0UVLAnWFFjGF9+vtVuFRtzjniiimBJIoIGR0NCKM9KKKXUaJFUEHOT1708ooTcBzjrmiimUPjRTDkjJpTGpAyKKKkY+JFKkEcfWtbw1Ei65Y4XH7xT+tFFC3IZ6vRRRWxmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marshfield Clinic. Copyright &copy; 2005 Marshfield Clinic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29994=[""].join("\n");
var outline_f29_18_29994=null;
var title_f29_18_29995="Prognostic features CLL";
var content_f29_18_29995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognostic features in chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Good prognostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low Rai or Binet clinical stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial or nodular pattern of lymphocyte infiltration in marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocyte doubling time &gt;12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD 38 negativity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutated immunoglobulin Vh genes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ZAP-70 negativity (low levels)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromosome 13q14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Poor prognostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High Rai or Binet stages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse pattern of lymphocyte marrow infiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocyte doubling time &lt;12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD 38 positivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unmutated immunoglobulin Vh genes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ZAP-70 positivity (high levels)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Del 11q23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17p-/p 53 abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        p 53 dysfunction or increased expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased levels of TNF-alpha, beta-2 microglobulin, IL-6, IL-8, IL-10, LDH, VEGFR-2, CD20, and CD52",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29995=[""].join("\n");
var outline_f29_18_29995=null;
var title_f29_18_29996="Injury severity";
var content_f29_18_29996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of injury severity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anatomic region",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head",
"       </td>",
"       <td>",
"        <p>",
"         Fall &lt;3 feet or from standing height",
"        </p>",
"        <p>",
"         Blow to head with no LOC and small hematoma",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Blow to head with brief LOC",
"        </p>",
"        <p>",
"         Superficial penetrating injury to the scalp (BB gunshot wound)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Blunt head trauma with GCS &le;12",
"        </p>",
"        <p>",
"         Intracranial penetrating head trauma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck",
"       </td>",
"       <td>",
"        Restrained passenger of MVC with &lt;20 mph (32 kph) force",
"       </td>",
"       <td>",
"        <p>",
"         Pedestrian hit by a car",
"        </p>",
"        <p>",
"         Bicyclist hit by a car",
"        </p>",
"        <p>",
"         Fall &gt;10 feet or 3x standing height",
"        </p>",
"        <p>",
"         Penetrating injury not deep to the platysma muscle",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Blunt neck trauma with palpable stepoff or neurologic deficit",
"        </p>",
"        <p>",
"         Diving injury with neck pain and paresthesias down both arms",
"        </p>",
"        <p>",
"         Penetrating neck trauma deep to the platysma muscle",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thorax",
"       </td>",
"       <td>",
"        Punch to chest wall with superficial bruise and normal respirations",
"       </td>",
"       <td>",
"        Pleuritic pain or significant bony tenderness after blunt trauma",
"       </td>",
"       <td>",
"        <p>",
"         Blunt trauma with hypoxemia or dyspnea",
"        </p>",
"        <p>",
"         Penetrating chest trauma with shock",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdomen",
"       </td>",
"       <td>",
"        Hit in the stomach by a soccer ball kicked by a playmate",
"       </td>",
"       <td>",
"        <p>",
"         Blunt trauma with abdominal tenderness or hematuria",
"        </p>",
"        <p>",
"         Restrained MVC passenger with a contusion from the seat belt",
"        </p>",
"        <p>",
"         Penetrating wound superficial to the peritoneum",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Blunt trauma with shock",
"        </p>",
"        <p>",
"         Penetrating trauma deep to the peritoneum",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extremities",
"       </td>",
"       <td>",
"        <p>",
"         Fall on outstretched hand with no deformity",
"        </p>",
"        <p>",
"         Twisted ankle with lateral malleolar swelling but no deformity",
"        </p>",
"       </td>",
"       <td>",
"        Extremity injury with obvious deformity",
"       </td>",
"       <td>",
"        <p>",
"         Crush injury with pallor and pain",
"        </p>",
"        <p>",
"         Penetrating injury with vascular compromise",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LOC: loss of consciousness; GCS: Glasgow coma scale; MVC: motor vehicle collision.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29996=[""].join("\n");
var outline_f29_18_29996=null;
var title_f29_18_29997="AGAI management GERD 3";
var content_f29_18_29997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AGAI management GERD (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What maintenance therapy is indicated for patients with suspected extraesophageal reflux syndromes (asthma, laryngitis, cough)? When and how should antisecretory therapy be decreased or discontinued?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Acute or maintenance therapy with once- or twice-daily PPIs (or H2RAs) for patients with a suspected extraesophageal GERD syndrome (laryngitis, asthma) with a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Maintenance therapy with once- or twice-daily PPIs (or H2RAs) for patients with potential extraesophageal GERD syndromes (laryngitis, asthma) in the absence of a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Once- or twice-daily PPIs for patients with suspected reflux cough syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are the clinical consequences of chronic potent acid inhibition? Do these potential side effects warrant specific testing (eg, bone density studies, calcium supplementation, Helicobacter pylori screening, and so on)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Advocating bone density studies, calcium supplementation, Helicobacter pylori screening, or any other routine precaution because of PPI use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the role of endoscopy in long-term management of patients with GERD, and under what circumstances should mucosal biopsy specimens be obtained when endoscopy is performed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Endoscopy with biopsy for patients with an esophageal GERD syndrome with troublesome dysphagia. Biopsies should target any areas of suspected metaplasia, dysplasia, or in the absence of any visual abnormalities, normal mucosa (at least 5 samples to evaluate for eosinophilic esophagitis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Routine upper endoscopy in the setting of chronic GERD symptoms to diminish the risk of death from esophageal cancer.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Endoscopic screening for Barrett's esophagus and dysplasia in adults 50 years or older with &gt;5-10 years of heartburn to reduce mortality from esophageal adenocarcinoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are indications for antireflux surgery, and what is the efficacy of this therapy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. When antireflux surgery and PPI therapy are judged to offer similar efficacy in a patient with an esophageal GERD syndrome, PPI therapy should be recommended as initial therapy because of superior safety.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. When a patient with an esophageal GERD syndrome is responsive to, but intolerant of, acid suppressive therapy, antireflux surgery should be recommended as an alternative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Antireflux surgery for patients with an esophageal GERD syndrome with persistent troublesome symptoms, especially troublesome regurgitation, despite PPI therapy. The potential benefits of antireflux surgery should be weighed against the deleterious effect of new symptoms consequent from surgery, particularly dysphagia, flatulence, an inability to belch, and postsurgery bowel symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade C: balance of benefits and harms is too close to justify a general recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Patients with an extraesophageal GERD syndrome with persistent troublesome symptoms despite PPI therapy should be considered for antireflux surgery. The potential benefits of antireflux surgery should be weighed against the deleterious effect of new symptoms consequent from surgery, particularly dysphagia, flatulence, an inability to belch, and postsurgery bowel symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Antireflux surgery for patients with an esophageal syndrome with or without tissue damage who are symptomatically well controlled on medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Antireflux surgery as an antineoplastic measure in patients with Barrett's metaplasia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. The use of currently commercially available endoluminal antireflux procedures in the management of patients with an esophageal syndrome.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kahrilas PJ, Shaheen NJ, Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008; 135:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29997=[""].join("\n");
var outline_f29_18_29997=null;
var title_f29_18_29998="DCF for advanced gastric cancer";
var content_f29_18_29998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy regimens for advanced esophagogastric cancer: Docetaxel, cisplatin, and fluorouracil (DCF)",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Docetaxel",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        750 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL 5 percent dextrose in water and administer as a continuous infusion over 24 hours. For use in an ambulatory infusion pump. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.",
"       </td>",
"       <td>",
"        Days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or IV sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for two hours before and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone prior to docetaxel administration",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Docetaxel and cisplatin are irritants, but can cause significant tissue damage; avoid extravasation",
"        <sup>",
"         [2,3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF indicated (incidence of neutropenic fever 29 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Docetaxel should not be given if serum bilirubin is above the ULN, or if the AST and/or ALT &gt;1.5 x ULN concomitant with alkaline phosphatase &gt;2.5 x ULN",
"        <sup>",
"         [3]",
"        </sup>",
"        . Dose modifications of FU may be needed for patients with hepatic impairment",
"        <sup>",
"         [4]",
"        </sup>",
"        . The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown; such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential and platelet count prior to each cycle of treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel including creatinine and electrolytes, and liver function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity, diarrhea, and palmar plantar erythrodysesthesias prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Patients should not be retreated until neutrophils recover to &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets recover to &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        <sup>",
"         [3]",
"        </sup>",
"        . If the platelet count declines to &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        during therapy, reduce subsequent doses of docetaxel by 20 percent. After the first episode of ANC &lt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        lasting &gt;7 days or febrile neutropenia or neutropenic infection despite G-CSF support, reduce docetaxel dose by 20 percent",
"        <sup>",
"         [3,5]",
"        </sup>",
"        . For a second episode, reduce subsequent doses of docetaxel by another 20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal dysfunction:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL",
"        <sup>",
"         [2]",
"        </sup>",
"        . For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 time normal value despite adequate rehydration), creatinine clearance should be determined prior to next cycle and cisplatin dose reduced if &lt;60 mL/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Reduce cisplatin dose 20 percent for grade &ge;2 peripheral neuropathy and discontinue for grade 3 neuropathy",
"        <sup>",
"         [2,5]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Gastrointestinal toxicity:",
"        </strong>",
"        Hold FU treatment for grade 3 or worse diarrhea and restart at a lower dose after complete resolution. For the first episode of grade 3 diarrhea or grade 3 or 4 stomatitis, reduce FU by 20 percent; subsequent episodes, reduce docetaxel 20 percent",
"        <sup>",
"         [3]",
"        </sup>",
"        . First episode of grade 4 diarrhea, reduce both docetaxel and FU by 20 percent; subsequent episodes, discontinue treatment.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar-plantar erythrodysesthesia:",
"        </strong>",
"        Hold FU for grade 2 or greater palmar plantar erythrodysesthesia, and reduce subsequent dose by 20 percent",
"        <sup>",
"         [6]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        Docetaxel should not be given if serum bilirubin is above the ULN, or if the AST and/or ALT &gt;1.5 x ULN concomitant with alkaline phosphatase &gt;2.5 x ULN",
"        <sup>",
"         [3]",
"        </sup>",
"        . For intracycle increases of AST/ALT &gt;2.5 but &le;5 times ULN, and alkaline phosphatase &le;2.5 times ULN",
"        <strong>",
"         OR",
"        </strong>",
"        AST/ALT &gt;1.5 to &le;5 times ULN",
"        <strong>",
"         AND",
"        </strong>",
"        alkaline phosphatease &gt;2.5 to &le;5 times ULN, reduce docetaxel by 20 percent",
"        <sup>",
"         [3]",
"        </sup>",
"        . Discontinue docetaxel if AST/ALT &gt;5 times ULN",
"        <strong>",
"         AND/OR",
"        </strong>",
"        alkaline phosphatase &gt;5 times ULN.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; ALT: alanine aminotranferease; AST: aspartate aminotransferase; G-CSF: granulocyte colony-stimulating factor; CBC: complete blood count; ULN: upper limit of normal.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Van Cutsem E, et al. J Clin Oncol 2006; 24:4991.",
"      </li>",
"      <li>",
"       Cisplatin for injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 10, 2011).",
"      </li>",
"      <li>",
"       Docetaxel for injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 10, 2011).",
"      </li>",
"      <li>",
"       Floyd J, et al. Semin Oncol 2006; 33:50.",
"      </li>",
"      <li>",
"       Ajani JA, et al. J Clin Oncol 2005; 23:5660.",
"      </li>",
"      <li>",
"       Fluorouracil for injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 10, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29998=[""].join("\n");
var outline_f29_18_29998=null;
var title_f29_18_29999="Sentinel node concept";
var content_f29_18_29999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Sentinel node concept",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 474px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Stone, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_18_29999=[""].join("\n");
var outline_f29_18_29999=null;
